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Introduction 
 
1.1 CELL CYCLE OF MAMMALIAN CELLS 
 
Mammalian cell cycle consists in a series of events that leads to DNA duplication and 
chromosomes segregation into two new daughter cells (Figure 1) [1] [2] [3]. These 
events can be divided in two steps: the first, known as interphase, consists in a transition 
phase through which cells prepare to divide; a second, called mitosis, consisting in the 
dividing process in two new daughter cells. In particular, the interphase can be 
separated in three more stages: a G1 phase where cells start to prepare for DNA 
synthesis, which takes place during the next phase, named S; finally, a G2 phase where 
cells prepare to divide. On the other hand, also the mitotic process can be divided itself 
in different steps: prophase, in which chromatin starts to condensate in chromosomes 
and two structures, called centrosomes, coordinate the microtubule synthesis and 
disposition; prometaphase where nuclear envelope disappears after phosphorylation of 
lamins and microtubules attach the chromosomes at the kinetochores; metaphase, 
through which the alignment of the chromosomes along the metaphase plate (equatorial 
plane) takes place; anaphase, where the chromosomes are dragged to the two 
extremities of the cell; telophase, during which decondensing cromosomes are 
surrounded by a new nuclear envelope; cytokinesis, already begun in late telophase, 
where the cell splits in two new daughter cells [1] [2] [3].  
                          
Figure 1 : Schematic representation of the cell cycle stages. G0: cell cycle is blocked 
and cells does not proliferate. G1: cells increase their contents and their size. S: 
duplication of the genetic chromosomes. G2: cells check the right chromosomes 
duplication and prepare for mitosis. Mitosis/Cytokinesis: several steps through which 
cells undergo division creating two new daughter cells.  
1.1.1 Cyclins, Cyclin-Dependent Kinases and cell cycle inhibitors 
All the steps through which a cell divides are strictly controlled and regulated by 
different proteins [4] [5] [6] [7] [8] [3]. Among these enzymes we can find the Cyclins, 
discovered for the first time in 1982 thanks to pioneering studies on sea urchin oocytes 
[9]. Cyclins are molecules characterized by oscillations strictly connected to the 
different phases of cell cycle progression, given by real fluctuations of their expression 
and degradation generally induced by the ubiquitin mediated system . Several isoforms 
of Cyclins are known to play a fundamental role in cell cycle regulation, such as 
Cyclins D, Cyclins E, Cyclins A and Cyclins B. The role of these proteins has been 
described to be regulatory: indeed, Cyclins are the regulatory molecules of the complex 
that they form with the Cyclin-Dependent Kinases (Cdk) [10, 11]. The expression of 
these phosphotransferases does not change along the cell cycle progression, but their 
activation is dependent by different mechanisms such as phosphorylations [10-12]. The 
complexes Cyclin-Cdk are activated in specific phases of the cell cycle regulating its 
progression until mitosis. Other proteins are involved in these processes. Among them, 
different kinases (Polo-Like Kinase 1, Cdk Activating Kinases, Wee1) and 
phosphatases (cdc25a/b/c) are known to play fundamental roles through cell cycle 
progression. In addition, it has been reported through the years the important role of 
Cyclin/Cdk inhibitors including the Cip/Kip (p21 and p27) and Ink4 Cdk (p15, p16) [4].  
 
1.2  SPECIFIC MODULATION OF CELL CYCLE 
CHECKPOINTS 
 
1.2.1 G1/S phase  
In this phase of cell cycle the D and E isoforms of Cyclins are involved (Figure 2)  [13-
15]. In particular, Cyclins D interact with Cdk4/6, fundamental complex for G1 entry 
[14]; once activated, Cdks phosphorylate the Retinoblastoma Protein (pRB), which, in 
its dephosphorylated form, is bound with the Elongation Factor 2 (E2F) [16] [17] [18]. 
Until the complex pRB-E2F is present, E2F cannot promote the G1/S transition of the 
cell cycle. The phosphorylations by Cdk4/6 on pRB allow the complex to split and the 
E2F to become active and affects its related targets [19]. Here, Cyclins E, interacting 
with Cdk2, starts to be highly synthesized, playing a fundamental role in the entry into 
the S phase [20, 21]. Notably, these events can be inhibited by the action of some 
molecules which inhibit the formation of the complexes between Cyclins and Cdks [22, 
23] . In particular, at these stages of the cell cycle, the most important inhibitors result 
to be the Cip/Kip p21, p27 and Ink4 Cdk p16. 
 
1.2.2 G2/M phase 
At the end of the S phase, Cyclin A/Cdk2/1 complexes lead the cells into early G2 
phase. Next, as widely described in literature [24-26], the formation of the Mitosis-
Promoting-Factor (MPF) , represented by Cyclin B1/Cdk1 interaction, leads the cells to 
enter into the mitotic process (Figure 2) [27]. MPF becomes active when Cdk1 is 
phosphorylated at Thr161 by Cdk activating kinases (CAK) and de-phosphorylated by 
Cdc25c at Thr14/Thr15 [28]. In addition, also Cyclin B1 has to be phosphorylated to 
promote the activation of the complex. Indeed, different kinases, such as Cdk1 and 
Polo-like kinase 1 (PLK1), add phosphates on a group of five Ser, the so called 
cytoplasmic retention signal (CRS) domain of Cyclin B1, which regulates its nuclear 
translocation at late prophase [29, 30]. The nuclear import of Cyclin B1/Cdk1 has been 
deeply described, but it remains not completely understood for the lack of a canonical 
nuclear localization signal (NLS) in Cyclin B1 structure, usually necessary for nuclear 
import of proteins through the karyopherins/importins system [31]. However, once in 
the nuclei, Cyclin B1/Cdk1 phosphorylates a wide number of substrates, such as 
Lamins, driving the cells into mitosis [27]. Finally, at the end of the mitotic process, 
Cyclin B1 begins to be degraded by the APC/C complex and Cdk1 undergoes 
inactivation leading cells to mitotic exit and cytokinesis [32, 33]. As well as for the 
G1/S transition, also the G2/M progression can be inhibited by several molecules. 
Indeed, the action of p21, Cip/Kip inhibitor, has been reported to be involved in the 
degradation of Cyclin B1 and, then, in the inhibition of the activity of the complex 
Cyclin B1/Cdk1 [34]. 
 
 
    
 
 
Figure 2: Cell cycle and cell cycle related proteins. G0/G1: Cyclin D/Cdk4/6 are 
involved in the phosphorylations of pRB, which in turn separates from the E2F leaving 
it able to trigger the transition to S phase. G1/S: Cyclins D begin to decrease while 
Cyclin E/Cdk2 complexes vehicle the cells through S phase. In late S phase, Cyclin 
A/Cdk2/1 regulate the entry in G2/M. G2/M: Cyclin B1/Cdk1, once activated, 
translocates into the nucleus and stimulates the events necessary for the start of the 
mitotic process. Ink4 (p16) and Cip/Kip (p21/p27) proteins inhibit the complexes 
Cyclin/Cdk along different phases, downregulating the cell cycle progression. Ref. [35] 
 
 
 
 
 
 
 
 
 
1.3 LIPID SIGNALLING 
 
Cell signalling is part of a complex network through which cells respond to different 
stimuli . The commonly known cell signalling can be represented in three steps: firstly, 
an extracellular molecule (grow factors, hormones, proteins) binds specific receptors 
situated on the membrane of the cells; second, these extracellular stimuli trigger a 
cascade of events within the cells, called signal transduction, which lead to the synthesis 
of second messengers; third, second messengers either activate or deactivate different 
cellular responses to which they are connected to. Among the molecules involved in the 
signal transduction system, lipids have been reported to be very important in the 
mediation of multiple cell activities such as proliferation, survival, differentiation, 
migration, cell cycle progression, metabolism and many others [36-38]. In particular, 
the production of second messengers starting from Phosphatidylinositol (PI) is the 
basement of multiple cell processes (Figure 3) [36-38]. PI consists of a hydrophilic 
inositol head group linked to glycerol by a phospho-diester bond, which in turn is 
coupled to two fatty acyl chains. One of the chains is often a saturated fatty acid 
(stearate), while the other is predominantly an unsaturated fatty acid (arachidonate).  
  
  
Figure 3 : Structure of Phosphatidylinositol (PI). The common PI structure is 
characterized by the presence of a hydrophilic inositol head group linked to a 
hydrophobic tail formed by glycerol through a phospho-diester bound. Glycerol, in 
turn, is connected with two fatty acids, often a saturated (stearate) and an unsaturated 
(arachidonate) acid. Ref. [39] 
 
 
1.3.1 PHOSPHATIDYLINOSITOL (PI) METABOLISM 
 
The metabolism of PI involves multiple enzymes such as kinases, phosphatases and 
lipases, which, in turn, modulate the pool of PI adding or removing phosphate groups on 
the inositol ring. These events lead to the production of 7 Polyphosphoinositides (PPIs), 
used as second messengers in different signalling cascades: Phosphatidylinositol 3-
Phosphate (PI3P), PI4P, PI5P, PI(3,4)P2, PI(3,5)P2, PI(4,5)P2, PI(3,4,5)P3. See Figure 4. 
As previously indicated, a large number of enzymes act at different levels along the PI 
metabolism and are involved in synthesis of new second messengers. Many kinases add 
phosphate groups on the inositol ring at different positions, such as Phosphatidyl-4-
kinase (PI4K), Phosphatidylinositol-3-kinase (PI3K), Phosphatidylinositol-phosphate 4-
kinase (PIP4K), PIP5K, PIP(4,5)K. On the other hand, some phosphatases, including 
phosphatase and tension homologue deleted on chromosome 10 (PTEN) and SH2-
domain containing inositol phosphatase 2 (SHIP2), act in the opposite way removing 
Phosphates [36-38]. Another class of enzymes involved in these processes is 
represented by the Phospholipases C (PLC), able to hydrolyze PI(4,5)P2 and produce 
DAG and Inositol-1,4,5-P3 (IP3). These two products are very important second 
messengers: DAG is fundamental for the activation of Protein Kinases C (PKC), while 
IP3 can either promote Ca2+ release from the ER stores, which in turn concurs in the 
activation of PKC, or be phosphorylated itself by several kinases to generate Inositol 
polyphosphates, some of which have been found to be involved in different signalling 
cascades [36-38].    
 
 
 
    
 
Figure 4 : A schematic representation of the PI metabolism. Starting from PI, 
different kinases add on the inositol ring phosphate groups in the different positions. 
The production of different Polyphosphoinositides (PPIs), used as second messengers, 
resulted fundamental for several signalling cascades. Other than kinases, some 
important phosphatases are involved in this network, characterized by the property to 
remove the phosphate groups from different positions on the inositol head group. Ref. 
[40] 
 
 
1.3.2 NUCLEAR LIPID SIGNALLING 
 
Although the common lipid signalling have been discovered half a century ago, over the 
past twenty years, many evidences reported the presence of different phospholipids in 
the nuclei of eucaryotic cells [39, 41, 42]. As expected, cell fractionation and isolation 
of nuclei indicated that lipids were present due to the presence of the nuclear envelope, 
which in eucaryotic cells is a double membrane composed by proteins and 
phospholipids, partly connected with the Endoplasmic Reticulum (ER) [43]. However, 
different studies showed that, after nuclear membrane removal through detergents, a 
significant amount of lipids was still detectable inside the nuclei [44, 45]. The first 
evidences about a proper nuclear lipid signalling separated by the cytoplasmic one were 
reported in mouse erythroleukemia cells (MEL), where nuclear Phosphatidylinositol-4-
phosphate (PI4P) and Phosphatidylinositol-4,5-biphosphate (PI(4,5)P2) were 
synthesized differently from the cytoplasmic counterpart [46]. Indeed, highly purified 
nuclei extracted from differentiating cells via Dimethyl sulfoxide (DMSO) showed the 
appearance of PI, PIP and PI(4,5)P2 instead of growing cells. Other studies performed 
on Swiss 3T3 cells showed that, upon stimulation of the cells with Insulin-like growth 
factor (IGF-1), the nuclear pool of PI4P and PI(4,5)P2 decreased with a concomitant 
increase of nuclear Diacylglycerol (DAG). On the other hand, Bombesin, which 
affected only the classical phosphatidylinositol signalling, did not lead to the same 
effects in the nuclear compartment [47-50]. These data confirmed the presence of  two 
distinct lipid signalling in eucaryotic cells, one located in the cytoplasms and one 
located within the nuclei. Changes in the nuclear pool of PIs have been found during 
cell cycle progression, differentiation, DNA damage, oxidative stress and many others 
stimuli (Figure 5).  
 
1.3.2.1 Nuclear DAG accumulation during cell cycle progression 
As already reported, the pool of PIs changes in the nuclei upon different stimuli. In 
particular, several studies showed changes in the production of DAG and IP3, related to 
the activity of specific PLCs located in the nuclear compartment [47-50]. Evidences 
collected in regenerating liver indicated an increased DAG production during cell 
proliferation [51]. Moreover, data collected on different leukemia cell lines, U937 and 
HL60, synchronized at G2/M, indicated that the amount of DAG raised in this phase of 
the cell cycle, particularly in the nuclei [52, 53]. This higher production of DAG was 
linked with the activity of a nuclear PLC isoform; indeed, experiments act to inhibit 
PLC activity led to a minor production of DAG. Finally, as consequence of these 
events, nuclear translocation of DAG-dependent PKC isoforms was detectable. Here, 
these phosphotransferases were found able to phosphorylate different targets, such as 
Lamins, and promote the G2/M progression [49, 54, 55].  
 
 
 
Figure 5: Nuclear Lipid Signalling: focus on PLCβ1 activation. Different stimuli 
external at the cell, such as the binding of grow-factors to specific membranes 
receptors, activate several signalling cascades which, using second messengers, 
transduce the signal in order to obtain a cellular response. Nuclear cell signalling is 
characterized by different activation stimuli. Indeed, activation of PLCβ1 is different 
between the nucleus and the cytoplasm. Once activated, PLCβ1 produces DAG through 
the nuclear PIP2 hydrolysis. This event is particularly connected with the different 
stages of cell cycle and leads to a nuclear translocation of some DAG-dependent PKC 
isoforms, including PKCα and PKCβII, capable to phosphorylate Lamins and trigger 
nuclear envelope breakdown during mitosis. Ref. [39]  
 
 
 
 
 
 
1.4 PHOSPHOLIPASES C (PLC) FAMILY 
The Phospholipases C represent a family of enzymes involved in the PI metabolism [56] 
[57]. The substrate of this class of proteins is PIP2, which is hydrolyzed to generate 
DAG and IP3. The first discover of PLC activity was reported in pigeon's pancreas 
slices, where hydrolysis of phospholipids took place after cholinergic stimulation [58]. 
In 1981, the first PLC isozyme was purified with a molecular weight of 68 kDa [59]. 
Through the years, many PLC were found and now the PLC family comprehends 13 
isoforms divided in different classes, due to their aminoacidic composition (Figure 6) 
[60].   
                                     
              
Figure 6 : Phospholipase C family of proteins. PLC enzymes are involved in the PI 
metabolism through the PIP2 hydrolysis. The activation of the PLC class of proteins is 
linked to various external stimuli: if the class γ  is activated by the RTK activation, 
PLCβ isoforms are linked to the GPCR receptors. The lipase activity of these proteins 
results fundamental for the production of DAG and IP3, which in turn triggers Ca2+ 
release from the Endoplasmic Reticulum. These two second messengers are known to be 
very important for the attraction to the membrane and the activation of a class of 
phosphotransferases, PKC, involved in many cell functions. Ref. [57] 
1.4.1 DOMAIN STRUCTURE 
 
1.4.1.1 Catalytic domains 
The domain composition of these enzymes is characterized by the presence of two 
catalytic domains, X and Y, where some fundamental amino-acidic residues for the 
activity of PLC reside (Figure 7) . Evidences reported on the structural analysis of 
PLCδ1 indicated Lys438, Lys440, Ser522 and Arg549 residues very important for the 
interactions of these enzymes with 4- or 5-phosphate of the substrate headgroup 
(PI(4,5)P2) [61].  Moreover, in mammalian PLC-δ1 two fundamental aminoacids were 
indicated as the catalytic residues, His311 and His356 [62, 63]. In particular during 
phosphoinositide hydrolysis, His311 participates to the stabilization of the highly 
negative charged transition state together with calcium, while His356 takes part both in 
diacylglycerol protonation and in the hydrolysis of the cyclic intermediate [61] [62, 63]. 
In particular, a study performed on myogenic differentiation  of C2C12 cell line showed 
that mutation of the His331 and His378 of PLCβ1 could inhibit its catalytic activity as 
well as for PLCδ1. This was confirmed by the fact that Cyclin D3 promoter expression, 
found to be positively modulated by PLCβ1 action, was not affected by the catalytic 
inactive mutant of the protein characterized by substitution of these two residues with 
two Ala [64]. 
 
1.4.1.2 PH domains 
The Pleckstrin-Homology domains contained in PLC mediate their binding with 
different molecules; in PLCδ1, PH domain is fundamental for the binding of PIP2 and 
the subsequent access to the membrane surface [65]. On the other hand, PH domains of 
PLCβ2 and PLCβ3 bind directly to the heterotrimeric G protein subunit, Gβγ [66]. 
Moreover, PH domain of PLCγ has been reported to interact PIP3, important for the 
PI3K-dependent PLCγ activation [67]. This PLC class is characterized by the presence 
of two PH domains, divided by two Src Homology domains (SH2) and a Src Homology 
(SH3) domain (Figure 7) [68].   
 
 
 
 
1.4.1.3 C2 and EF-hands domains 
The C2 domain of PLC contains some aminoacidic residues which allow the protein to 
bind Ca2+ in order to enhance the lipase activity of the enzyme [69]. Otherwise, EF-
hands motifs can be very important for the control of PLC activity; indeed, mutations on 
this domain decreases PLC activity, in a Ca2+ independent way (Figure 7) [70, 71]. 
 
 
 
Figure 7 : Schematic representation of the PLC classes and domains. 13 PLC 
isoforms are known in eucaryotic cells. Every PLC isozyme shares some important 
domains with the others such as X and Y catalytic domains, PH domains (PLCγ is 
characterized by two PH of them), C2 (Ca2+ sensitive) and EF-hands regulatory 
domains. All the classes of PLC are represented by more than one isoforms, which are 
characterized by different splicing variants (such as PLCβ1 with PLCβ1a and 
PLCβ1b). Ref. [57] 
 
1.4.2 PLC ISOFORMS: FOCUS ON PLCβ 
 
Thirteen PLC isoforms, divided in 6 classes, are known to be present in eucaryotic cells. 
The different members of the classes are commonly present in different forms; indeed, 
splicing variants of every gene that encodes PLC isozymes are present in the cells and 
influence their localization in the tissues and in the cellular compartments [72, 73]. In 
particular, two spicing variants of the gene encoding for PLCβ1 are known as PLCβ1a 
and PLCβ1b, which differ each other in the C terminal sequence [74, 75]. PLCβ1 is 
member of the PLCβ class, which comprehends PLCβ1~4 [76]. These enzymes share 
with the other classes part of the characteristic structure of PLC: they possess a 
conserved catalytic domain, split in X and Y regions, as well as two membrane-
phospholipid binding domains such as C2 and PH domains [77, 78]. However, PLCβ 
isozymes are distinguished by differences in the C-terminal sequence of their structure. 
Indeed, these molecules are characterized by an elongated C-terminus consisting in 
about -450 aminoacids, which contain different important residues for the interaction 
with membranes and for their localization in the cells [76-78]. PLCβs are regulated by 
G-protein-coupled-receptors (GPCR), which activate G-protein mediated signal 
transduction [76]. The G-proteins form a heterotrimeric structure in the inactive GDP-
binding state comprehending Gα, Gβ and Gγ subunits. When GPCR is stimulated, Gα, 
which binds GDP (Guanosine Di-Phosphate) in the inactive state, exchanges GDP with 
GTP (Guanosine Tri-Phosphate) causing its dissociation from Gβγ dimer [79, 80].  Both 
the complexes GTP-Gα and Gβγ dimers are important for signal transduction which 
leads to PLCβ activation [76]. Moreover, the Gα-GTPase activity is also involved in the 
inactivation of the signalling GPCR-dependent through the hydrolysis of GTP in GDP 
and the return of the heterotrimeric structure, Gα-β-γ binding GDP [79, 80]. However, 
several studies showed the PLCβ isoforms are characterized by different responsiveness 
to the GPCR mediated signalling: indeed, PLCβ1 results to be the least sensitive to the 
Gβγ-dependent activation, while PLCβ4 is completely insensitive to Gβγ [81−83]. 
Moreover, the Gα subunit can be divided in 4 isoforms: Gsα, Giα, Gqα e G12α. Among 
them, Gq subtype comprehends four members (αq, α11, α14 e α16), all able to activate 
PLCβ1 [84]. Gqα activation site has been indicated to reside in the C-terminus of 
PLCβ1. On the other hand, the activation mediated by Gβγ dimers is due to the binding 
at the N-terminus of the PH domain [85].  
1.4.2.1 PLCβ1 splicing variants: PLCβ1a and PLCβ1b 
The gene encoding PLCβ1 is located on chromosome 20 and encodes two different 
splicing variants of the proteins, PLCβ1a (150kDa) and PLCβ1b (140kDa) [74]. These 
two isoforms of PLCβ1 conserve the typical structure of the PLCβ class of PLCs, but 
differ each other for the C-terminus. Indeed, PLCβ1b replaces 75 residues in the C-
terminal sequence with a sequence of 43 aminoacids [86, 87]. This difference resulted 
to be very important for the distribution of the enzyme among the different cell 
compartment. Indeed, PLCβ1 is known to be one of the pivotal enzymes involved in 
nuclear cell signalling. Several studies indicated this PLC as completely localized in the 
nucleus, others showed it as more cytoplasmic. The differences in these reports can be 
linked to the existence of two splicing variants of PLCβ1. The 1b isoform is 
characterized for the lack of a common Nuclear Exportation Signal (NES), located in 
the C-terminus of the protein, which, on the contrary, is contained in PLCβ1a structure. 
Moreover, both the variants possess a Nuclear Localization Signal (NLS) (Figure 8) 
[86]. This NLS has been described to be located at the C-terminus. Indeed, the 
overexpression of a mutant of PLCβ1 (M2b), characterized by the substitution of 
Lysine1056, 1063 and 1070 at C-terminal, markedly reduced the nuclear localization of the 
enzyme in various cell lines [88]. Particularly, PLCβ1 resides in specific nuclear 
structures called nuclear speckles, small subnuclear membraneless organelles or 
structure corresponding to nuclear domains located in interchromatin regions of the 
nucleoplasm of mammalian cells [45, 89-92]. Together with PLCβ1, several other 
molecules and enzymes are known to be located in these nuclear compartments, such as 
PIP kinase, PI3KC2α, PIP2, diacylglycerol kinase θ (DGK θ), PLC-δ4, phosphatase and 
tension homologue deleted on chromosome 10 (PTEN) and SH2-domain containing 
inositol phosphatase 2 (SHIP2) [45, 89, 90]. 
 
 
 
 
            
 
  
Figure 8 : PLCβ1 splicing variants, PLCβ1a and PLCβ1b. Both the isoforms present 
in their C-terminal a sequence fundamental for the nuclear import called Nuclear 
Localization Signal (NLS). The main differences in their structure are found always in 
C-terminal: PLCβ1b lacks a series of residues where in PLCβ1a the Nuclear 
Exportation Signal (NES) is localized. Then, PLCβ1b results to be mainly nuclear, 
while PLCβ1a is situated in both nuclear and cytoplasmic compartment. Ref. [86] 
 
 
1.4.2.2 PLCβ1 mediated nuclear signalling 
The nuclear production of IP3 and DAG mediated by the activity of PLCβ1 has been 
widely described in literature [47] [49, 93]. However, how PLCβ1 is activated at 
nuclear level remains unclear. Indeed, the mechanism which triggers PLC signalling in 
the nucleus resulted different from the one located in the cytoplasm. Some evidences 
reported the possibility for the Giα subunit to translocate in the nucleus, while others 
indicated, as the main candidate for PLCβ1 activation, p42/44 MAPK (Mitogen 
Activated Protein Kinase). Indeed, experiments performed in order to inhibit p42/44 
activity or its nuclear translocation showed a minor activation of nuclear PLCβ1 in 
different cell lines [94-96]. In particular, it was also reported that PLCβ1 possesses a 
phosphorylation site for p42/44 in the C-terminus, the residue Ser982 [97]. However, this 
phosphorylation cannot activate PLCβ1 but is thought to be important for the 
recruitment of other regulatory elements which stimulate the lipase activity of the 
enzyme.  On the other hand, the inactivation of the PLCβ1 dependent nuclear signalling 
seems to be related to the phosphorylation by PKCα of the residue Ser887, which seems 
to modulate the capacity of PLCβ1 to bind Gβγ dimers in vitro [98].  
 
1.4.2.3 PLCβ1 involvement in cell cycle and cell differentiation 
Several reports indicated cell cycle and cell differentiation as highly connected with 
PLCβ1 mediated metabolism. Studies on MEL cells suggested an involvement of this 
lipase in these two important processes. Indeed, experiments on MEL, inducted to 
differentiate by Dimethyl-sulfoxide (DMSO) treatment, indicated a high decrease of 
PLCβ1 amount in the cells, which was followed by inhibition of its nuclear activity [39, 
46, 93, 99]. In particular, it has been found that the nuclear localization and activity of 
the enzyme was important during differentiation . In order to study that, PLCβ1 and 
M2b mutant (only cytoplasmic) were overexpressed in differentiating MEL. The result 
was a minor expression of the differentiating marker of this cell line, β-globin, which 
followed to the increase of wild type PLCβ1, while in M2b overexpressing cells no 
changes in differentiation were encountered [100, 101]. Moreover, studies on PLCβ1 
involvement in cell cycle regulation showed its importance for both G1/S and G2/M 
checkpoints. Indeed, always using MEL cells, PLCβ1 has been found to have a positive 
correlation with Cyclin D3 expression, which led to an increase in Retinoblastoma 
Protein (pRB) phosphorylation and, then, to a consequent elongation of the S phase of 
the cell cycle [102]. Otherwise, PLCβ1 resulted also involved in the early stages of the 
mitotic process. Its activity was fundamental to induce nuclear translocation of some 
isoforms of PKC, which, in turn, were able to phosphorylate Lamin B1 driving the 
disassembly of the nuclear envelope and the progression through the G2/M phase [103]. 
 
 
 
 
 
 
 
 
 
 
1.5 PROTEIN KINASES C (PKC) FAMILY 
Protein kinases C (PKC) are serine/threonine phosphotransferases which belong to the 
AGC family of protein kinases (cAMP-dependent, cGMP-dependent, and protein kinase 
C) [104-106]. The first PKC was discovered in 1977 in old bovine brains as a 
proteolitically activated protein kinase able to phosphorylate Histones [107]. Then, in 
the early 1980s, these enzymes were found to be receptors of the tumor promoting 
phorbol esters, which raised their importance in signal transduction researches. Indeed, 
first PKC was cloned in the middle of 1980s and it was found to possess a C1 domain 
specific for phorbol esters binding [108-110]. Through the years, it became clear that 
these kinases can be involved in many cellular processes such as proliferation and cell 
cycle progression, differentiation, tumorigenesis, apoptosis and autophagy. The canonic 
dogma about their activation indicates that these proteins are dependent by PIP2 
hydrolysis mediated by the PLC family leading to the production of  DAG and IP3, 
which in turn triggers Ca2+ release from the Endoplasmic Reticulum (ER) [104-106].  
 
1.5.1 PKC CLASSES 
Nowadays, ten PKC enzymes are known in mammalian cells and are subdivided in 
three classes based on the differences in their domain composition, which indicate what 
cofactors are needed for their activation (Figure 9) [104, 105]. First, the conventional 
class is composed by four isoforms: PKCα, the two splicing variants PKCβI and 
PKCβII (which differ in their C-terminus for 43 amino acids) and PKCγ; next are the 
four novel isoforms, PKCδ, PKCε, PKCη and PKC θ; finally, the atypical class refers 
to PKCζ and PKCι/λ (ι human; murine isozyme is PKCλ). In addition, two more PKC 
isozymes are known, PKC µ and ν, which are considered either to belong to a fourth 
class of PKCs or to be member of a different family called Protein Kinases D [111]. 
 
1.5.2 DOMAIN STRUCTURE 
All the members of the PKC family share a common structure characterized by 
conserved (C1–C4) and variable regions (V1–V5) split in two main domains, the 
regulatory and the catalytic moieties connected each other by a hinge region. The 
regulatory domain of PKC isozymes consists in two main modules, C1 and C2 domains, 
which regulate the binding of DAG/Phorbol esters and Ca2+ respectively. In addition, 
aminoacidic residues close to the C1 domain are reported to act as an autoinhibitory 
sequence indicated as pseudosubstrate. On the other hand, the catalytic domain is 
represented by the ATP-binding site sequence and, at C-terminus, by some important 
aminoacids which, once phosphorylated, influence the maturation and, in turn, the 
activation of these phosphotransferases (Figure 9) [104-106].  
 
1.5.2.1 Regulatory domain 
 
1.5.2.1.1 Pseudosubstrate 
The pseudosubstrate domain of PKC is a stretch of aminoacids between residues 19 and 
36 which is responsible for maintaining the enzyme in the inactive form in absence of 
allosteric activators such as phospholipids [112]. Studies on PKC structure showed that 
this sequence was very similar to a common sequence substrate for PKC except an 
Alanine (Ala25) that occupied the phosphoacceptor Ser/Thr position. Synthetic peptides 
based on this sequence resulted good inhibitors for PKC, while substitution of Ala25 
with a Serine transformed the pseudosubstrate into a potent substrate [113].  
 
1.5.2.1.2 C1 domain    
Although the  C1 domain is present in all PKC isoforms, where it results to be the 
Phorbol Ester/DAG binding site, atypical class is characterized by a modified C1 
domain, not sensitive to these molecules. However, C1 domain is present in PKC as a 
tandem, C1A and C1B, which link DAG and Phorbol Esters respectively. It is a 
Cystein-rich sequence of approximately 50 aminoacids and it can be found also in other 
proteins not related to PKC family [114, 115]. Tri-dimensional studies showed a 
globular structure characterized by two β-sheets which constitute the ligand-binding 
pocket for DAG or Phorbol Esters. The binding of these molecules to the C1 domain 
results fundamental for the recruitment of PKC to the membranes, due to the changes in 
the surface properties of the module which becomes hydrophobic, a necessary step for 
membrane interaction [115]. 
 
1.5.2.1.3 C2 domain 
The C2 domain is the part of the regulatory moiety sensitive to Ca2+. It is present only in 
conventional and novel classes of PKC, while atypical one lacks it. However, novel 
isoforms are characterized by a C2 domain not sensitive to Ca2+ and, then, they are 
activated only by DAG or Phorbol Esters. Moreover, as C1 domain, C2 domain has 
been found in several molecules other than PKC. The localization of this module along 
the aminoacidic sequence changes within different PKC classes: conventional isoforms 
present it after the C1 domain, while in the novel is true the opposite. In particular, C2 
domain results to be a β-strand-rich globular domain that binds Ca2+ increasing the 
affinity of PKC for anionic phospholipids located at membrane levels, such as 
Phosphatidylserine (PS) or PIP2 [116-118].     
 
1.5.2.2. Catalytic domain 
 
1.5.2.2.1 ATP-binding site 
The catalytic domain of ABC kinases (PKA, PKCB/Akt and PKC) is highly conserved, 
with more than 40% of homology among the sequences. In particular, the kinase 
domain of PKC has been remained not well understood for years due to its refraction to 
crystallization. However, studies on PKCβII, θ and ι isoforms reported new information 
about the structure of the catalytic domain of this class of proteins which resulted to be 
a bilobal structure with a β-sheet comprising the N-terminal lobe and an α-helix 
constituting the C-terminal lobe. Both the ATP-(C3) and substrate-binding (C4) sites 
are located in the cleft formed by these two lobes [119-121]. 
 
1.5.2.2.2. C-terminus phosphorylation sites  
All the ABC kinases share three conserved phosphorylation motifs in the C-terminus 
(C4) which modulate their maturation and activation. These sites can be considered as 
switches that trigger changes in the molecular conformation of the enzyme and mediate 
the substrate phosphorylation [104-106].  
 
1.5.2.2.2.1. Activation loop 
This site is represented by Thr500 in the conventional PKCβII, Thr197 in PKA and Thr308 
in PKB/Akt. The kinase responsible for the phosphorylation on these residues resulted 
to be the 3-Phosphoinositide-dependent protein kinase-1 (PDK1) [122]. In particular, 
this is the first phosphorylation for PKC and it results to be constitutive for conventional 
and novel PKC, while it is agonist dependent for atypical isoforms [104, 105].  
 
1.5.2.2.2.2. Turn motif 
The phosphorylation on the turn motif is essential for the stabilization of the structure of 
mature PKC by anchoring the C-terminal tail on the upper lobe of the kinase. It takes 
place on Thr641 as indicated in studies performed on PKCβII. Substitution of this residue 
with Ala triggers compensating phosphorylations on adjacent Thr that accompany the 
maturation process of PKC. However, further mutations on these Thr inhibit these 
compensating events. The enzyme responsible of phosphorylation on the turn motif 
resulted to be the mammalian target of rapamycin complex 2 (mTORC2) [123-125].  
 
1.5.2.2.2.3. Hydrophobic motif 
The hydrophobic motif phosphorylation is the third and last phosphorylation which 
takes place on PKC structure leading to their activation. The residue where a phosphate 
group is added is Ser660 as reported by studies on conventional PKCβII. Kinetic 
analyses found that PKC are able to autophosphorylate themselves on this motif, while 
other studies indicated mTORC2 as the responsible for this event. Indeed, PKCδ 
hydrophobic motif phosphorylation is inhibited by treatment with rapamycin, while 
mTOR-deficient cells show no phosphorylation at all [123-126]. 
 
1.5.2.3. Atypical PKC domains 
As previously reported, this class of PKC is not activated by neither DAG nor Ca2+, but 
it needs protein-protein interactions. This is mediated by the two regions located in the 
regulatory and catalytic domains respectively: Phox/Bem1p (PB1) domain and 
postsynaptic density protein 95 (PSD95), Drosophila discs large tumor suppressor 
(Dlg1) and zonula occludens 1 (ZO-1) (PDZ) domains [104-106]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 : Classes and domain compositions of PKC family. PKC are divided in 
three different classes due to their domain composition: conventional (PKCα, βI, βII 
and γ), novel (PKCδ, ε, ν, η) and atypical (ζ, ι/λ). The structure of these enzymes is 
characterized by two principal moieties: one regulatory and one catalytic. The 
regulatory one of conventional isoforms is represented by a C1 (present in tandem, C1A 
and C1B) domain, able to bind DAG and Phorbol-Esters, and a C2 domain sensitive to 
Ca2+. Every enzyme presents a pseudosubstrate region, fundamental for autoinhibition 
of the enzymes. Novels possess a C2 domain not sensitive to Ca2+, while atypical class 
has an atypical C1 domain not able to bind Ca2+ and completely lacks the C2 domain. 
The catalytic domain of PKC is composed by the ATP-binding site and a C-terminus 
sequence where some important aminoacidic residues for maturation and activation 
reside. Atypical PKC present a PB1 and a PDZ domains which mediate protein/protein 
interactions fundamental for their activation. Ref. [106] 
 
 
 
 
 
 
 
 
 
1.5.3 PKC LIFE CYCLE  
As explained, PKC undergo three subsequent phosphorylations, fundamental for their 
maturation and activation (Figure 10) [104-106]. However, this process results to be 
influenced also by others molecules. Newly-synthesized PKC are linked to a fraction of 
the cell membrane due to several weak interactions between C1 and C2 domains with 
anionic lipids. Here, PKC interact with chaperone Heat-Shock protein 90 (HSP90) and 
the co-chaperone Cdc37, a necessary event for the phosphorylation of conventional and 
novel PKC. Experiments of inhibition of HSP90 and/or its mutation decreased the 
possibility of PKC to be phosphorylated [127]. Next, the three phosphorylation events 
take place thanks to the activity of PDK1 and mTORC2. The fully mature PKC is now 
located in the cytosolic fraction [104-106]. The PLC-dependent production of the two 
second messengers DAG and Ca2+, through PIP2 hydrolysis, is fundamental for the 
continuation of the process [56, 57]. Ca2+, bound by the C2 domain, is responsible for 
the attraction of PKC to the cell membrane where they tie anionic lipids as PS or PIP2. 
Moreover, C1 domain binds its membrane-ligand DAG. For novel isozymes, which lack 
a common C2 domain, the interaction between DAG and C1 domain results to be 
sufficient for their recruitment to the membrane [104-106]. These events provide the 
energy to release the autoinhibitory pseudosubstrate from the substrate-binding cavity, 
allowing the enzyme to recruit and phosphorylate its targets. The "open" conformation 
that PKC adopt once they are bound to membranes renders these enzymes sensitive to 
dephosphorylation on the hydrophobic motif mediated by the PH domain leucine-rich 
repeat protein phosphatase (PHLPP) [128]. This leads to the shift of PKC to detergent-
insoluble fraction where they are further dephosphorylated on the others motifs and 
degraded. Notably, PKC which present a dephosphorylated turn motif can bind HSP70, 
an event that promotes rephosphorylation of the molecule and, in turn, a longer lifetime 
[129]. Other scaffold proteins can regulate PKC life cycle, such as receptors for 
activated C kinase (RACKs), maintaining the proteins in autoinhibited form which 
avoids their dephosphorylation and subsequent degradation [130]. Interestingly, the 
inactive PKC are characterized by a quite long half-life, while a chronic stimulation that 
changes their conformation in open, as occurs upon Phorbol Esters treatment, leads to a 
rapid degradation of these isozymes. Indeed, open PKC undergo higher 
dephosphorylation than inactive/close, which makes them unstable and shunted to 
degradation [131, 132].  
 
 
 
Figure 10 : PKC life cycle: the steps for PKC activation and degradation. PKC 
maturation and activation take place trough different and subsequent phosphorylations: 
first, novel-synthesized PKC bind the membrane through C1 and C2 domains. Here, the 
interaction with HSP90 modulates the first phosphorylation by PDK1 on the activation 
loop at the C-terminus of the proteins. Then, PKC leave the membrane and are locate in 
the cytosol, where they are again phosphorylated on the Turn and Hydrophobic motives 
by mTORC2. Here, production of the second messengers DAG and IP3 (and Ca2+) leads 
to the recruitment of PKC to the plasma membrane where they bind PIP2 and/or PS. 
Next, dephosphorylation of the hydrophobic motif by PHLPP inhibits their activity and 
leads them to degradation. However, binding with HSP70 can start again PKC 
phosphorylation and reactivation, prolonging their life cycle. Ref. [105] 
 
 
 
 
 
 
 
 
1.5.4 PKC SIGNALLING AND CELL CYCLE REGULATION 
The importance of PIP2 hydrolysis related signalling in cell cycle progression has been 
widely discussed through the years [55, 106, 133] [100-102, 134]. In particular, the 
involvement of PKC in cell proliferation and differentiation has been found highly 
connected with the progression through the different checkpoints of cell cycle (Figure 
11). What has emerged by many reports is that the effects mediated by PKC are mostly 
context-dependent. As a matter of fact, different roles for PKCs were described in cell 
cycle machinery both as anti-proliferative and growth-stimulatory enzymes. Indeed, 
single PKC isoforms can affect more molecules, such as Cyclins, Cdk, cell cycle 
inhibitors, depending by cell models, signalling environment and cell cycle phase [106] 
[133]. Both in vitro and in vivo experiments indicated specific effects of PKC isozymes 
during both G1/S transition and in G2/M progression [135]. In particular, the activation 
of PKC has been negatively correlated with Cyclins D expression in intestinal crypt 
cells, by different modulation of the cell cycle inhibitors p21 and p27 [136]. Another 
study indicated PKCα as capable to phosphorylate p27 in vitro [137]. Moreover, other 
isoforms, such as PKCδ and η, have been reported to regulate Cyclin D1 and Cyclin E 
[138-140]. Other functions of PKC have been found during G2/M progression where 
the nuclear translocation of these molecules, due to an increase in nuclear DAG 
production, resulted fundamental for their activity [141]. Indeed, reports on leukemia 
cell lines, such as HL60 and MEL, showed that the nuclear translocation of PKCβII and 
PKCα at G2/M checkpoint led to phosphorylation of Lamins, necessary for the 
disassembly of the nuclear envelope and progression through mitosis [103, 142]. 
Another possible mechanism of modulation of cell cycle mediated by PKC is the 
regulation of nuclear lipid signalling. Indeed, as cell cycle progression has been widely 
described to be connected to the signal transduction based on PIP2 hydrolysis, it has 
been reported that nuclear translocation of PKCα can downregulate it through the 
phosphorylation of PLCβ1 on Ser887, which inhibits the activity of this enzyme and, in 
turn, the production of nuclear DAG [98]. 
  
 
Figure 11 : PKC involvement in cell cycle modulation. PKC have been reported to 
be highly connected with cell cycle at multiple levels. Different PKC isoforms 
(PKCα, PKCδ, PKCε and PKCη) can regulate G1/S transition targeting  
Cyclins D/E /Cdk4/6/2 complexes or INK4-Cip/Kip inhibitors. G2/M progression: less 
information are reported about this phase of cell cycle. PKC can modulate Cyclin 
A/Cdk2 or phosphorylations of nuclear Lamins. Ref. [106] 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Aim  
As inositol lipid signalling has been found fundamental in cell cycle and cell 
differentiation of several murine models, we decided to study its role also in human 
models. In particular, we focused our attention on signal transduction mediated by the 
activity of nuclear PLCβ1, member of the PLC family, enzymes able to cleave PIP2 
creating DAG and IP3. For our purpose, we decided to use a human erythroleukemia 
cell line (K562), characterized by a high accumulation of this PLC isoform in their 
nuclear compartment. First, we started seeking possible involvements of this protein in 
the G1/S phase of cell cycle. Considering previous findings on MEL cells, we studied 
the possible connection between PLCβ1 and Cyclin D3. We found that the activity of 
PLCβ1 was fundamental for Cyclin D3 expression. Indeed, overexpression of the 
enzyme led to a positive modulation of its expression and to a prolonged S phase of the 
cell cycle. Then, we decided to better elucidate which mechanism could be responsible 
of these effects. We focused on the possible involvement of the direct targets of PLC 
signalling, the PKC family. As K562 cells express only two DAG-dependent PKC 
isoforms, PKCα and PKCβII, we found that an overexpression of PLCβ1 was able to 
decrease the levels of PKCα in our model [143]. Mimicking the effects of PLCβ1 
overexpression, we directly silenced PKCα finding a concomitant upmodulation of 
Cyclin D3 and a very similar cell proliferation of the cells. These evidences indicated 
that the PLCβ1/PKCα pathway could be very important in G1/S transition of cell cycle. 
Moreover, as PIP2 related signalling can be involved also in G2/M checkpoint, we 
investigated new possible targets for PKC during this phase. Interestingly, we found 
that PKCα was able to positively affect Cyclin B1 expression, independently by its 
kinase activity. Indeed, PKCα was found to act as a scaffold protein for Cyclin B1 
avoiding its degradation along cell cycle progression. Moreover, both the proteins 
accumulated into the nucleus at G2/M checkpoint. The main factor responsible of this 
event was nuclear DAG accumulation during this phase, which was connected to the 
increased activity of nuclear PLCβ1  during mitosis. These evidences indicated new 
roles for PLCβ1 and PKCα during G2/M progression. Then, in this thesis, new 
pathways and signalling cascades linked to nuclear PIP2 hydrolysis are described as 
very important cell cycle modulators both at G1/S and G2/M. The manuscript will be 
split in two parts: a first part where the involvement of PLCβ1 and PKCα in G1/S will 
be elucidated; a second that will show how these two enzymes could regulate also the 
G2/M progression of cell cycle of human erythroleukemia cell line, K562.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
2.1 Cell culture 
Human erythroleukemia cells (K562) were grown in RPMI 1640 (Sigma Aldrich) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) and L-
glutamine/streptomycin (1X), at 5% CO2 and 37°C.  
 
2.2 Cell treatments  
Cells were treated with the following compounds: Phorbol 12-myristate 13-acetate 
(PMA, Sigma Aldrich) at a final concentration of 50-100nM for 30 minutes or 16 hours 
(in order to stimulate nuclear translocation of PKC and their degradation respectively), 
U73122 (Sigma Aldrich, PLC inhibitor) at 10µM for 16 hours, with Go6976 and 
Go6983 at 1µM (Sigma Aldrich, PKC inhibitor) and with 3-(1-(3-imidazol-1-ylpropyl)-
1H-indol-3-yl)-4-anilino-1H-pyrrole-2,5-dione-anilinomonoindolylmaleimide 
(Calbiochem, PKC inhibitor) at 1µM for 24 hours [144]. Finally, MG-132 (Sigma 
Aldrich, proteasome inhibitor) was used at a final concentration of 15µM for 2 hours. 
 
2.3 Cell synchronization  
Cells were collected as described below for the experiments: (1) G1/S cells: 
proliferating cells were cultured in complete RPMI 1640 FBS 10%; (2) G2/M blocked 
cells: growing cells were treated with Nocodazole (Sigma Aldrich) at a final 
concentration of 20ng/ml for 16h; (3) G0/G1 cells: growing cells were starved in Hank's 
Balanced Salt Solution (HBSS, Sigma Aldrich) for 16 hours. After synchronization, 
cells were seeded again in complete RPMI 1640 FBS 10% and left to grow for 
experiments of cell cycle analysis and cell counting. In experiments where PKCα was 
overexpressed, cells were partially stimulated to undergo G2/M accumulation adding 
Nocodazole for 6 hours at a final concentration of 20ng/ml. 
 
2.4 Protein extraction and Western Blotting Analysis 
Cells were collected by centrifugation, washed in PBS and lysed in mPER lysis buffer 
(BIORAD) containing protease inhibitors (Thema Ricerca) for at least 30 minutes at 
4°C. Next, homogenates were centrifuged for 5 minutes at 13000 rpm at 4°C in order to 
remove any insoluble elements and the surnatant moved in new vials. The protein 
concentration of the samples was detected via Spectrophotometer analysis using a 
Bradford protein assay (Bio-Rad). Briefly, empty vials were filled with 800µl of H2O 
plus 200µl of Bradford reagent. Then, 1µl of every lysate was added to the mix while 
1µl of mPER lysis buffer was used as the white sample to set the instrument. Note that 
every measurement was made in triplicate. The assorbance of the samples at 595nm was 
measured using a spectrophotometer and the protein concentration was detected 
comparing the values of the lysates with the values of a standard BSA curve already 
prepared. Next, samples for western blotting analysis were prepared as follows: every 
lysate was added of Laemli Sample Buffer 4X and water in order to have the same 
volume and same protein amount. Then, 50µg of samples were separated on SDS-
PAGE and electro-transferred to nitrocellulose membranes at 400mA for 1:30h. 
Ponceau Red staining was used to control the occurred transfer of proteins. Membranes 
were washed in PBS-0.1%/Tween-20 (PBS/T) and nonspecific binding sites were 
blocked by incubation in blocking buffer (PBS/T with 5% non-fat dry milk) for 1 h at 
room temperature. After several PBS/T-washes, membranes were incubated with 
specific primary antibodies overnight at 4°C. The day after, membranes were washed 
again at least 3 times, then incubated with peroxidase conjugated secondary antibodies 
diluted in PBS/T for 1 h at room temperature. After several washing passages, proteins 
were detected by incubating membranes in enhanced chemiluminescence detection 
system (ECL, Thema Ricerca). Antibodies were as follows: PLCβ1, Cyclin D3, Cyclin 
B1, PKCα, PKCβII, PKCζ, Lamin A/C  from Santa Cruz, PKCα, Cyclin B1, Cyclin A, 
Cyclin E, phospho-Cyclin B1 Ser133, phospho-Cyclin B1 Ser147, Cdc25c, Cdk1/cdc2, 
phospho-Cdk1/cdc2 Tyr15, Cdk4, Cdk6, Cdk7 from Cell Signaling technology and β-
tubulin from Sigma Aldrich. Analysis with an antibody for β-tubulin demonstrated 
equal protein loading. Every antibody was diluted as indicated by the manufacturer's 
instructions. 
 
2.5 Flow Cytometric analysis of cell cycle  
For FACS analysis 1 × 106 cells were collected by centrifugation at 1,200 rpm for 5 min 
at 4°C and washed twice in ice-cold PBS. Cells were fixed (and permeabilized) with 
−20°C cold 70% ethanol overnight at 4°C. Fixed cells were, then, washed in PBS twice 
and resuspended in 1 ml of staining solution (40 μg/ml propidium iodide and 100 μg/ml 
RNase A in PBS). The samples were incubated for at least 30 min at room temperature 
in the dark. FACS analysis was performed, and the percentage of cells in different 
phases of the cell cycle was assessed using a FC500 flow cytometer equipped with cxp 
software (Beckman Coulter Inc.). At least 10,000 events per sample were acquired. 
 
2.6 Cell transfections and Isolation of stable clones 
Cells were transfected with full-length DNA vectors for human PKCα (Addgene, 
plasmid number 21232 and 21235, [145]), PLCβ1a or PLCβ1b using empty pcDNA/2.1 
plasmid (Invitrogen) as control. Overexpressions were performed using Lipofectamine 
2000 from Invitrogen. Cells were seeded at a cell density of 5 × 105/ml in 6-well plates, 
to which was added the mix of Lipofectamine 2000 (Life Technologies) and right 
vectors, following manufacturer’s instructions. In order to obtain stable clones 
overexpressing PLCβ1a and PLCβ1b, cells were selected by limiting dilution in 
complete RPMI 1640 10% FBS containing Geneticin (G418 from Sigma Aldrich) at a 
concentration of 1000µg/ml starting 72h after the transfection, then expanded and kept 
always in selection with G418. The expression of PKCα, PKCβII and PLCβ1 was 
silenced by RNAi at a final concentration of 50nM using the electroporation assay kit 
by Thema Ricerca: cells, plated at a cell density of 2 x 106/ml before the transfection, 
were resuspended in 100µl of Mirrus Solution (pre-warmed at 37°C); specific siRNAs 
were added at the suspension and the mix moved in proper cuvettes. Using program T-
16, cells were electroporated in Nucleofector I (Amaxa). Afterwards, cells were plated 
in 25ml flasks with 5ml of complete RPMI 1640 10% FBS. The following siRNAs were 
used: in order to silence PLCβ1 s23358 and s23359 (Applied Biosystems), to silence 
PKCα s11092, s11093 and s11094 (Applied Biosystems), to silence PKCβII 
s11095 (Applied Biosystems). As negative control a mix of Silencer Select Negative 
Control #1 and #2 siRNAs (Applied Biosystems). 
 
2.7 Mutagenesis 
For our purpose, we used the catalytic inactive mutants of PLCβ1a and PLCβ1b created 
by mutations of His331 and His378 in the putative active site of the enzymes. The 
substitution of the two residues with two Ala was performed on the plasmids encoding 
PLCβ1a and PLCβ1b using the QuickChange XL II site-directed mutagenesis kit from 
Stratagene (La Jolla, CA). Two subsequent mutagenesis reactions were performed: the 
first reaction using primer I (5′-CTA TTT CAT CAA TTC CTC AGC CAA CAC CTA 
CCT CAC AGC TG-3′) and primer II (5′-CAG CTG TGA GGT AGG TGT TGG CTG 
AGG AAT TGA TGA AAT AG-3′) to obtain His331 → Ala, was followed by a second 
reaction performed on the resulting mutated vector using primer III (5′-GAA GAG CCT 
GTC ATC ACC GCT GGA TTC ACC ATG ACA AC-3′) and primer IV (5′-GTT GTC 
ATG GTG AAT CCA GCG GTG ATG ACA GGC TCT TC-3′) to obtain His378 → Ala. 
All mutations were verified by DNA sequencing [64]. 
 
2.8 Nuclear/Cytoplasmic separation 
Cells were collected, centrifuged and washed in PBS 1X. PBS 1X was accurately 
removed and the pellets were resuspended in 1ml of TM2 buffer (hypotonic buffer 
containing 10 mM Tris-HCl pH 7.4 and 2 mM MgCl2) for 2 minutes. Then, Triton 0.6% 
was added and everything was passed twice through a syringe with a 22 ½ gauge 
needle. Preliminary controls of nuclear purity have been performed through microscope 
analysis. Next, MgCl2 3mM was added to the solution, which was centrifuged for 10 
mins at 0.8 rpm. The nuclear pellets were washed twice in TM5 buffer (isotonic buffer 
containing 10 mM Tris-HCl pH 7.4 and 5 mM MgCl2), while the supernatant was 
transferred in a new vial and used like a cytoplasmic control. The nuclei were lysed 
using mPER (as total lysates) to which DNAse (Invitrogen) was added to remove the 
possible chromatin contamination. 
 
2.9 Immunoprecipitation 
Cells were lysed in mPER lysis buffer (BIORAD) containing protease inhibitors 
(Thema Ricerca). 500µg of proteins were pre-cleared adding 20µl of Protein A/G 
PLUS-Agarose (Santa Cruz) for 1 hour at 4o C. Then, beads were centrifuged and the 
supernatant transferred in another vial. 500 µl of protein lysates were incubated 
over/night with the appropriate primary antibodies on wheels at 4o C. The day after, 
25µl of  Protein A/G PLUS-Agarose were added for 1h at 4o C. Beads were centrifuged 
and pellets washed 3 times with mPER. Immuno-complexes were resuspended in 
loading buffer (4X), boiled at 95°C  for 5 minutes, resolved on SDS/PAGE and 
transferred on nitrocellulose. After incubation with the indicated antibodies, antibody–
protein interactions were detected with enhanced chemiluminescence detection system 
(ECL, Thema Ricerca). As positive control 50µg of proteins from total lysates of K562 
were loaded on SDS/PAGE gel.   
 
2.10 Immunofluorescence microscopy 
Cells were seeded on electrostatically charged glass slides using a Shandon Cytospin 
(Thermo Electron Corporation, Pittsburgh, PA, USA) at low acceleration and 200 rpm 
for 5 min. Slides were fixed in 4% paraformaldehyde at 37°C for 10 min and 
permeabilized with 0.1% Triton X-100 in PBS for 8 min. Then slides were blocked with 
PBS containing 5% BSA for 1h. Incubation with monoclonal anti-PLCβ1, PKCα or 
Cyclin B1 (1:100) (Santa Cruz) was performed overnight at 4°C in blocking medium 
and then with FITC-conjugated anti-mouse immunoglobulin G (IgG) antibody (1:200) 
or Cy3-conjugated anti-rabbit IgG antibody (1:100) (Sigma-Aldrich) for 1 h at room 
temperature. Slides were washed 3 times for 10 min at room temperature with PBS 1X / 
Tween 0,1% and mounted with a DAPI anti-fade reagent in glycerol (Molecular Probes, 
Eugene, OR, USA). Images were taken on a Zeiss Axio Imager Z1 microscope, 
equipped with 60X/NA 1.4 optics and Apotome apparatus, coupled to a computer 
driven Zeiss AxioCam digital camera (MRm), using Zeiss Axio Vision 4.4 software 
(Carl Zeiss, Oberkochen, Germany). At least 100 cells per slide were analyzed. 
 
2.11 RNA extraction, Retrotranscription and  qPCR  
Transfected K562 cells were collected and total cellular RNA was extracted using the 
RNeasy minikit (Ambion) according to the manufacturer’s instructions. The purity and 
amount of RNA were analyzed measuring their assorbance at 260-280nm through 
Nanodrop. 2 µg of total RNA were reverse transcribed using 0.5µg of Oligo(dT) 15 
Primer and sterile H2O was added to the solution up to a final volume of 15µl. The mix 
was incubated for 5 minutes at 70o C to eliminate all the secondary structures of RNA. 
Next, Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT), RNAse 
and dNTPs (Promega) were added following the manufacturer's instructions in order to 
obtain a 25µl solution. Gene expression of PLCβ1a, PLCβ1b, PKCα and Cyclin B1 was 
determined by using the 7300 real-time PCR system. Briefly, the reaction was 
performed in MicroAmp Optical 96-well plates at a final volume of 25µl. Every 
solution was composed using 12.5µl of TaqMan® Gene Expression Master Mix 
(Applied Biosystems), 1µl of cDNA, 1.25µl of the right probe (specific for the gene of 
interest) and 10,25 µl of H2O. Every sample was analyzed in triplicate and the results 
were normalized to the level of the ubiquitously expressed RNA 18S ribosomal 1 gene 
(RN18S, Hs03928990_g1) and were expressed as 2-∆∆Ct. The reaction conditions were 
as follows: 2 minutes at 50o C, 10 minutes at 95o C followed by 40 cycles at 95o C of 15 
seconds and 1 minute at 60o C. For PKCα the Hs00925193_m1, for PLCβ1a the 
Hs01008373,  for PLCβ1b the Hs01001939,  for Cyclin B1 the Hs00820463_g1 probes 
were used (Applied Biosystems). 
 
2.12 Statistical analysis 
Statistical analyses were performed by Student t-test, using GraphPad Prism (GraphPad 
Software Inc. version.6) (* P < 0.05, ** P < 0.001, *** P < 0.0001). 
 
2.13 Cell counting  
To determine cell growth, cells were synchronized using Nocodazole or starvation in 
RPMI without FBS. 24 hours later, the block was removed seeding them in complete 
RPMI 10% FBS at a cell density of 1 x 105/ml in 6-well plates. Growth curves were 
determined by direct counting of cells harvested for 24, 48 and 72 h after seeding. 
Viable cells were handly counted by a hemocytometer using 0.2% Trypan Blue. 
 
2.14 Quantification of DAG  
K562 cells were cultured and synchronized as previously described. Nuclei or intact 
cells were labeled with [3H]-glycerol (10µCi/ml/1 x 106 cells) for 90 minutes. Next, 
nuclei and total cells were precipitated with 10% TCA and, then, 10 volumes of 
chloroform/methanol/concentrated HCl (300:300:1.5) were added and lipids extracted 
for 20 hours at 4oC. After centrifugation, supernatants were preserved and the pellets 
were re-extracted twice with 10 volumes of chloroform/methanol/concentrated HCl 
(400:200/1.5). The combined supernatants were dried under steam of nitrogen and lipids 
were dissolved in 100µl of chloroform and washed three times in 4 volumes of 
chloroform/methanol/water (3:48:47). Finally the samples were dried under a steam of 
nitrogen and [3H]-labelled lipids were analyzed by TLC on silica gel 60 plates 
developed with ether/exane/NH4 (50:50:0.25). TLC plates were sprayed with Enhancer 
(Du Pont, NEN) and fluorographed at -80o C. Spots corresponding to lipids were 
scraped off, extracted with 1.5ml of 0.6N HCl-Methanol (60:40 by volume) for 48 
hours with gentle stirring and counted with a liquid scintillation counter using 9ml of 
Packard Pico-Fluor 40 scintillation cocktail . 
 
2.15 PLC activity assay  
The activity of nuclear PLCβ1 was assessed using a specific protocol set by Martelli et 
al. PLCβ1 was silenced and, 48h later, nuclei and cytoplasms were separated. A 
scramble siRNA was used as control. 60µg of nuclear proteins were treated with 3nmol 
[3H]-PIP2 (specific activity 30000 d.p.m./nmol), 100mM MES, 150nM NaCl, 0.06% 
taurodeoxycholate and reaction was performed for 30 minutes at 37o C. Hydrolysis of 
PIP2 was stopped adding HCL-chloroform-methanol and the aqueous phase was 
separated from the organic one through centrifugation at 2000g for 5 minutes. PIs 
recovered from the aqueous phase were analyzed by HPLC. The amount of radioactivity 
corresponding to IP3 was analyzed (in counts per second, c.p.s.) [47].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Results 
3.1 INVOLVEMENT OF PLCβ1 AND PKCα IN THE 
MODULATION OF CYCLIN D3 EXPRESSION AND CELL 
PROLIFERATION OF K562 CELL LINE 
 
3.1.1 Human erythroleukemia cells, K562, overexpressing PLCβ1 show 
increased levels of Cyclin D3  
In order to understand whether PLCβ1 could regulate expression of Cyclin D3 also in 
human erythroleukemia cells as well as in murine models [102], we used a model of 
human cell line, K562, transiently transfected with two vectors encoding the two 
splicing variants of PLCβ1, PLCβ1a and PLCβ1b. An empty vector was used as control 
for the experiments. Cells, seeded at a cell density of 5 x 105/ml were transfected to 
overexpress these enzymes and, 24 hours later, were collected and lysed to extract their 
protein content. Total lysates were analyzed via western blotting in order to study the 
possible modulation of cell cycle related proteins due to the increase of PLCβ1 in the 
cells. Interestingly, we found that the overexpression of both the isoforms of PLCβ1 
(PLCβ1a OV and PLCβ1b OV)  could lead to an important increase of Cyclin D3 levels 
if compared with the controls (Empty vector). We screened also some others cyclins and 
Cdks, such as Cyclin A, Cyclin E, Cdk6 and Cdk4, which did not show any change in 
their expression. These findings indicated that the connection between PLCβ1a and 
PLCβ1b with Cyclin D3 was positive and specific. Indeed, no other molecules were 
targeted by PLCβ1 increase (Figure 12).  
                   
 
                              
 
Figure 12 : PLCβ1 overexpression positively affects only Cyclin D3 levels. K562 
cells were transfected in order to overexpress both the splicing variants of PLCβ1, 
PLCβ1a and PLCβ1b (PLCβ1a OV/ PLCβ1b OV). An empty vector was used as control 
(Empty Vector). Lysates were analyzed via Western Blotting and the expression of 
several proteins involved in cell cycle progression was studied. 
 
3.1.2 PLCβ1 leads to a delay in cell proliferation prolonging the S phase 
of the cell cycle in proliferating K562 cells 
In order to understand if the positive effects of overexpression of the splicing variants 
PLCβ1a and PLCβ1b on Cyclin D3 could influence the behavior of the cells in terms of 
proliferation and cell cycle progression, we decided to create stably transfected clones 
overexpressing PLCβ1a, PLCβ1b and the empty vector (PLCβ1a OV, PLCβ1b OV and 
Empty vector). K562 cells were seeded at a density of 5 x 105/ml in complete RPMI 
1640 10% FBS and transfected using a Lipofectamine 2000 protocol, following 
manufacturer’s instructions. After the transfections, we kept the cells growing and 
recovering for 72 hours and, then, we added G418 to the medium to start the selection 
of stable clones. A week later, the specificity and the quality of PLCβ1 isoforms 
overexpression in the stable clones was analyzed via qPCR using specific probes for 
each splicing variant (Figure 13a). Once we obtained stably transfected cells, we started 
to focus our attention on cell cycle and cell proliferation analyses. As Cyclin D3 is 
involved is G1 phase [13-15], we synchronized K562 clones at G0/G1 phase. Briefly, 
cells were grown for two days and blocked at G0/G1 by 24h of starvation in RPMI 1640 
without FBS. After this treatment, cells were split in two aliquots: one was collected 
immediately (24h starved cells) and one was centrifuged, washed in sterile PBS 1X and 
seeded back in complete RPMI 1640 with FBS for another 24h. The day after, also this 
second aliquot (proliferating cells) was collected. Analyses via western blotting and 
FACS were performed in order to study the modulation of Cyclin D3 in stable clones 
overexpressing PLCβ1a and PLCβ1b and the subsequent effects on cell cycle 
progression. As shown in Figure 13b and c, starved cells were characterized by 
accumulation at G0/G1 with no modulation of Cyclin D3 expression in all the clones. 
On the contrary, proliferating clones overexpressing PLCβ1 showed an increased 
Cyclin D3 expression and a prolonged S phase if compared with the control. In 
addition, in order to better understand the meaning and the effects of these differences 
in the S phase among clones, we decided to study which was their behavior in terms of 
cell proliferation. Cells were then grown for three days, seeded in 6-wells at the same 
number and, then, counted after 24-48-72 hours. As shown in Fig. 12D, clones 
overexpressing both the isoforms of PLCβ1 were characterized by a decrease in cell 
proliferation compared with the controls. These data confirmed a role of PLCβ1 in G1/S 
transition: targeting Cyclin D3 in proliferating cells, overexpression of both the 
isoforms of PLCβ1 prolonged the S phase of the cell cycle leading to a severe slow-
down of cell proliferation in K562 cells.   
  
 
 
Figure 13 : PLCβ1a and PLCβ1b overexpression leads to an increase of Cyclin D3 
in proliferating cells, followed by a prolongation of the S phase of cell cycle and a 
slow-down of cell proliferation. a) Real-Time analyses showed the specific stable 
overexpression of the two PLCβ1 isoforms, PLCβ1a and PLCβ1b. b) Cells stably 
overexpressing PLCβ1 (PLCβ1a OV / PLCβ1b OV) and controls (Empty Vector) were 
starved for 24h. One aliquot was collected and lysed, one was seeded again in complete 
RPMI 1640 with FBS for other 24h and, then, lysed. Western Blotting analyses showed 
an increase of Cyclin D3 in clones overexpressing PLCβ1 only in proliferating 
conditions. c) Cells were treated as in b) and cell cycle analysis via FACS was 
performed. d) Clones overexpressing PLCβ1a or PLCβ1b and the controls were seeded 
in 6-well plates and counted for 24-48-72h. 
 
 
 
3.1.3 PLCβ1a and PLCβ1b overexpression leads to a decrease of PKCα  
As PLCβ1 and Cyclin D3 were found connected to the regulation of K562 cell cycle, 
we decided to further investigate the pathway through which this modulation could take 
place. Then, we studied the class of protein known to be directly activated by PIP2 
hydrolysis, the PKC family [104-106]. Several previous findings reported the 
involvement of these phosphotransferases in cell cycle progression through effects on 
cyclins, cyclin-dependent kinases and cell cycle inhibitors [106, 133]. K562 cells 
resulted a very good model to study PKC signalling, because only three isoforms are 
expressed in this cell line: conventional PKCα and PKCβII and atypical PKCζ [143]. 
Thus, we screened their expression in cells stably overexpressing PLCβ1a and PLCβ1b 
(PLCβ1a OV, PLCβ1b OV and Empty vector as control). As previously described, cells 
were synchronized and lysed. Lysates were analyzed via Western Blotting and the 
expression of these PKC was evaluated with specific antibodies. Interestingly, 
overexpression of both PLCβ1 splicing variants led to a strong decrease in PKCα 
levels, while PKCβII and PKCζ resulted not to be affected at all (Figure 14). These data 
indicated a possible connection between PLCβ1 signalling and PKCα during K562 cell 
proliferation.           
                           
                                    
 
Figure 14 : PLCβ1 overexpression leads to a downregulation of the levels of PKCα. 
PKCβII and PKCζ are not affected. PLCβ1a and PLCβ1b (PLCβ1a OV / PLCβ1b 
OV) were overexpressed in K562 cells. Empty vector was used as control (Empty 
Vector). Western Blotting analyses were performed to analyze the expression of the 
PKC isoforms expressed in K562 cells. 
 
 
3.1.4  PLCβ1 activity is necessary for PKCα decrease 
In this series of experiments we decided to understand if the lipase activity of PLCβ1 
was necessary in PKCα modulation. In order to achieve that, we transfected the cells 
with two catalytic inactive mutants of the two splicing variants of PLCβ1. As explained 
in materials and methods, these two vectors were characterized by two substitutions on 
two fundamental residues for the activity of PLCβ1; in particular His331 and His378 were 
substituted with two Ala [64]. Data obtained demonstrated that overexpression of a 
catalytic inactive mutant of PLCβ1 did not affect the expression of PKCα if compared 
with the wild type vectors and the controls  (PLCβ1a OV, H331/H378 1a OV, PLCβ1b 
OV, H331/H378 1b OV and Empty vector) (Figure 15). These evidences strengthened 
the idea that PLCβ1 signalling could be responsible for PKCα downmodulation in this 
cell line.  
           
 
                      
 
Figure 15 : The catalytic activity of PLCβ1 is necessary for PKCα downregulation. 
Cells were transiently transfected to overexpress PLCβ1a or PLCβ1b (PLCβ1a OV / 
PLCβ1b OV) and catalytic inactive mutants of both the isoforms (H331/H378 1a OV / 
H331/H378 1b OV). An empty vector was used as control (Empty Vector). The expression 
of PKCα was analyzed via Western Blotting.   
 
 
 
 
 
3.1.5 PKCα knock-down mimics PLCβ1 overexpression in terms of 
Cyclin D3 expression and cell proliferation 
As PLCβ1 mediated regulation of both PKCα and Cyclin D3 resulted clear, here we 
decided to investigate if PKCα modulation could be important for Cyclin D3 expression 
and, in turn, for cell cycle and cell proliferation. Then, mimicking the effects of PLCβ1 
overexpression, we directly silenced PKCα through siRNA techniques (see materials 
and methods). Cells were transiently transfected with a specific siRNA for PKCα and a 
scrambled one as control (PKCα KD and Scrambled). 24 h later, they were collected 
and lysed. Western Blotting analyses showed a strong up-regulation of the levels of 
Cyclin D3 in PKCα knock-down conditions if compared with the control. Moreover, 
other proteins involved in cell cycle regulation were screened and resulted not affected 
by PKCα. Thanks to these evidences, we found the involvement of PKCα in Cyclin D3 
regulation (Figure 16a). Moreover, we also thought to study if PKCα silencing could be 
important for the slow-down of K562 cell proliferation, as found in cells overexpressing 
PLCβ1a or PLCβ1b. Then, we transfected the cells in order to silence PKCα as already 
described; two hours later we moved the cells in 6-well plates at the same concentration. 
Finally, we counted them in triplicate after 24-48-72 hours (Figure 16b). Cells 
characterized by a silenced PKCα resulted slower than the controls in terms of cell 
proliferation. Taken together, the collected data demonstrated the similar behavior of 
cells overexpressing PLCβ1 or with PKCα knock-down; in particular, both the proteins 
resulted to be part of the same pathway which regulated Cyclin D3 expression and, in 
turn, cell proliferation of K562 cells.  
                 
 
 
 
 
 
 
                    
 
 
Figure 16: PKC silencing leads to an up-modulation of Cyclin D3 levels and to 
slow-down of cell proliferation, which results the same encountered in cells 
overexpressing PLCβ1. a) PKCα was transiently silenced (PKCα KD) and, 24h later, 
Western Blotting analyses were performed to screen different proteins involved in cell 
cycle progression. A Scrambled siRNA was used as control (Scrambled). b) Cells were 
transfected to silence PKCα and counted for 24/48/72 hours. 
 
 
 
3.2 NUCLEAR DAG PRODUCTION DURING CELL CYCLE 
IS LINKED TO PLCβ1 ACTIVITY, WHICH RESULTS 
FUNDAMENTAL FOR THE REGULATION OF THE 
COMPLEX REPRESENTED BY PKCα AND CYCLIN B1 
 
3.2.1 PKC decrease affects Cyclin B1 levels in cells synchronized at G2/M 
As previously reported, no evidences about a possible involvement of PKC in the 
regulation of Cyclin B1/Cdk1 complex have been reported so far. In order to study if 
the two DAG dependent PKC isoforms present in K562 cells, PKCα and PKCβII, could 
affect Cyclin B1, we treated the cells with three different PKC inhibitors: Go6983, 
Go6976 and 3-(1-(3-imidazol-1-ylpropyl)-1H-indol-3-yl)-4-anilino-1H-pyrrole-2,5-
dione anilinomonoindolylmaleimide (from here simply PKC inhibitor*), at a final 
concentration of 1µM for 16h. This concentration renders these compounds specific for 
conventional and novel isoforms. Notably, all the compounds were ATP-competitor 
drugs which inhibit the activity of PKC [144], but PKC inhibitor* resulted also capable 
to highly down-modulate the levels of these proteins, due probably to off targets effects 
on other molecules involved in PKC life cycle (Go6983, Go6976, PKC inhibitor* and 
Control). However, in all the experiments, cells were synchronized at G2/M using 
Nocodazole, an inhibitor of the microtubules synthesis, to avoid any cell cycle 
dependent oscillation of Cyclin B1 expression. We found that cells treated with PKC 
inhibitor* showed an important decrease of Cyclin B1 levels if compared with the 
controls. Surprisingly, the only inhibition of PKC activity by Go6983 and Go6976 did 
not affect this Cyclin isoform at all. On the contrary, we decided to increase PKC 
signalling using 12-O-tetradecanoylphorbol-13-acetate (TPA), also called phorbol-12-
myristate-13-acetate (PMA), at a final concentration of 50nM. This phorbol-ester 
compound acts as a potent tumor promoter and activator of PKC, through the binding 
with C1B domain. As previously reported, a chronic/hyper activation of these 
phosphotransferases leads to their faster degradation due to changes in their structure 
[131, 132]. However, cells were blocked at G2/M as previously reported and the levels 
of Cyclin B1 were studied via Western Blotting analyses. Interestingly, PKC down-
regulation due to PMA action (PMA and Control) was followed by a high down-
regulation of the levels of Cyclin B1 in the cells. These findings indicated that, more 
than the activity, the presence of PKC in the cells could be fundamental for the 
regulation of Cyclin B1 in K562 cell line (Figure 17). 
 
 
Figure 17 : PKC positively regulate the levels of Cyclin B1 in K562 cells 
synchronized at G2/M. Cells were treated with three different PKC inhibitors 
(Go6983, Go6976 and 3-(1-(3-imidazol-1-ylpropyl)-1H-indol-3-yl)-4-anilino-1H-
pyrrole-2,5-dione anilinomonoindolylmaleimide (PKC inhibitor*)) at a final 
concentration of 1µM or with PMA at 50nM for 24 hours. Then, they were synchronized 
by treatment with Nocodazole (16 hours at 20ng/ml) at G2/M. Western Blotting 
analyses of the lysates were performed to control the expression of PKCα, PKCβII and 
Cyclin B1. 
 
3.2.2 PKCα is the only conventional isoform able to modulate Cyclin B1 
expression and, in turn, cell cycle progression 
As it is commonly known that inhibitors can have many off target effects, in particular 
if used at high concentration, we decided to understand if PKC could be really involved 
in the mechanisms behind Cyclin B1 regulation and, in particular, which isoform 
between PKCα and PKCβII was responsible of that. Then, we transiently transfected 
K562 cells to silence PKCα or PKCβII using a Scrambled siRNA as control (PKCα 
KD, PKCβII KD and Scrambled). 24h later, we added Nocodazole to synchronize them 
at G2/M. Western Blotting analyses showed that the only PKC isoform capable to affect 
Cyclin B1 was PKCα. PKCβII silencing had no effects on this enzyme at all (Figure 
18a). Moreover, as Cyclin B1 can be phosphorylated on a CRS region composed by 5 
residues of Ser, we investigated if some of them could be modulated by PKCα silencing 
[29, 30]. We found that neither Ser133 nor Ser147 were affected (data not shown). 
Finally, we focused our attention on cell cycle profile of cells characterized by PKCα 
knock-down and, then, to decrease of Cyclin B1. 24h after transfection, cells were 
synchronized at G2/M with Nocodazole. Then, the block was released seeding them 
again in complete RPMI 1640 10% FBS where they were left to grow for 24h. Cell 
cycle analyses by FACS revealed that silencing of PKCα led to an increase of the 
percentage of cells in G2/M compared to the controls, probably due to their difficulty to 
exit this stage of the cell cycle for the lack of Cyclin B1 (Figure 18b).  
 
Figure 18: PKCα is the PKC isoform responsible for Cyclin B1 modulation. This 
regulation leads to effects on the G2/M progression of cell cycle. a) Cells were 
transiently transfected to silence PKCα or PKCβII (PKCα KD / PKCβII KD). A 
Scrambled siRNA was used as control (Scrambled). 24h later, they were synchronized 
at G2/M using Nocodazole. Lysates were analyzed via Western Blotting. b) Cells were 
transfected and, 24h later, synchronized at G2/M with Nocodazole. Then, the G2/M 
block was removed seeding the cells in complete RPMI 1640 10% FBS for 24h. Cell 
cycle was analyzed via FACS.  
 
3.2.3 PKCα overexpression increases Cyclin B1 levels in K562 cells: the 
kinase activity of the enzyme resulted not to be necessary for this effect 
In this series of experiments we decided to understand if PKCα activity was necessary 
for Cyclin B1 modulation. Then, using two different vectors, one encoding a wild type 
PKCα (WT) and one a dominant negative mutant of the protein (DN, given by a 
puntiform mutation in the ATP-binding site, Lys376 was substituted with Arg), we 
overexpressed the enzyme in the cells. An empty vector was used as control. 24h later, 
Nocodazole was added for only 6h, in order to drive the cells to Cyclin B1 increase and, 
in turn, to G2/M accumulation. This partial synchronization was performed to avoid a 
complete block and high increase of the levels of Cyclin B1, which could render the 
differences among the samples  impossible to be detected. Notably, we found an up-
modulation of Cyclin B1 levels in cells characterized by overexpression of either PKCα 
WT or DN if compared to the controls (PKCα WT OV, PKCα DN OV and Empty 
vector). Interestingly, no differences between the WT or DN samples were encountered 
(Figure 19a). This was a further indication that the kinase activity of PKCα was not 
necessary in this mechanism. Moreover, cell cycle analyses indicated that 
overexpression of both the PKCα vectors led to a faster G2/M accumulation of the cells, 
probably connected to a major presence of Cyclin B1 in the system (Figure 19b).      
 
Figure 19 : Overexpression of a wild type or dominant negative PKCα leads to the 
same modulation of Cyclin B1 and to the same cell cycle profile in K562 cells. Cells 
were transiently transfected to overexpress PKCα using a wild type vector (PKCα WT 
OV) and a dominant negative mutant (PKCα DN OV). Empty vector was used as 
control (Empty Vector). Partial synchronization was obtained adding Nocodazole for 
6h, in order to stimulate G2/M and Cyclin B1 accumulations. Lysates were analyzed via 
Western Blotting and cell cycle profile via FACS. 
 
3.2.4 Absence of PKCα triggers Cyclin B1 degradation 
Since we found a positive correlation between PKCα and Cyclin B1, we decided to 
deeply study how this modulation could work. Then, we thought to understand at which 
level it could take place. First, we performed a gene expression analysis via real-time 
PCR. We silenced or overexpressed PKCα and synchronized the cells as previously 
described. RNA extracted was retrotranscribed to obtain cDNA, which was used for the 
real-time PCR. Notably, no changes in gene expression of Cyclin B1 have been found 
(Figure 20a), suggesting the existence of a post-transcriptional mechanism of regulation 
by PKCα. As Cyclin B1 undergoes degradation after the G2/M progression, we 
investigated the possible involvement of PKCα in this process. In order to study that, 
we transiently silenced PKCα and, 24h later, we divided the cells in two aliquots. One 
of them was treated with a proteasome inhibitor, MG-132, at a final concentration of 
15µM for 2h, to inhibit Cyclin B1 degradation. Western Blotting analyses showed an 
accumulation of Cyclin B1 levels in cells treated with this compound compared with the 
control (Figure 20b) (PKCα KD, PKCα KD + MG-132 2h). These evidences suggested 
that the presence of PKCα could limit Cyclin B1 degradation in K562 cells. Moreover, 
as further control of this findings, we decided to screen the levels of the Cip inhibitor 
p21, known to be involved in this process [34]. Indeed, its levels have been found to 
raise during Cyclin B1 degradation. Then, we silenced PKCα and synchronized cells at 
G2/M. PKCα knock-down cells were characterized by a strong increase of p21/Cip1 
expression concomitant with Cyclin B1 down-modulation (Figure 20c) (PKCα KD and 
Scrambled). All these data indicated that lack of PKCα drove to a faster degradation of 
Cyclin B1 in K562 cells. 
                     
Figure 20 : PKCα is involved in mechanisms that mediate Cyclin B1 degradation. 
a) Cells were transfected to silence or overexpress PKCα and gene expression of PKCα 
and Cyclin B1 were analyzed via real-time PCR. b) PKCα was silenced for 24h, then, 
cells were split in two aliquots, one of them was treated with the proteasome inhibitor 
MG-132 for 2h at a final concentration of 15µM. c) PKCα was silenced and cells 
synchronized at G2/M. Both the lysates of b) and c) were analyzed via Western Blotting. 
3.2.5 Cyclin B1 and PKCα share the same behavior during cell cycle 
progression and are able to interact in the cytoplasmic fraction 
In order to study the localization and the expression of PKCα and Cyclin B1 along the 
cell cycle progression, we decided to set a protocol to specifically synchronize K562 
cells in the different cell cycle phases. First, we starved them over/night with HBSS to 
obtain a partial synchronization at G0/G1; G1/S phase was referred to proliferating cells 
in complete RPMI 1640 10% FBS; finally, Nocodazole was again used for G2/M arrest 
(Figure 21a). Western Blotting analyses of total lysates of cells in the different cell 
cycle stages showed a progressive increase of Cyclin B1 and PKCα peaking at G2/M. 
In particular, separating nuclei from cytoplasms, we found an important G2/M related 
accumulation of both these molecules in the nuclear fraction (Figure 21b) (G0/G1, G1/S 
and G2/M). This similar behavior of the two enzymes was also confirmed by 
immunocytochemistry experiments (Figure 21c). Furthermore, considering their 
colocalization along cell cycle progression, we decided to understand if they could be 
part of a common complex of proteins. Then, we Co-Immunoprecipitated both the 
enzymes in cells synchronized at G2/M. Interestingly, we found a perfect interaction 
between them. As data obtained by IP techniques could be misleading, we decided to 
control the quality of our experiments. First, as positive control, we pulled down both 
Cyclin B1 and PKCα developing the following Western Blotting with specific 
antibodies to detect these same enzymes. Data obtained showed that the experiments 
were performed properly. Second, we immunoprecipitated again both the proteins with 
Cdk1/cdc2, the Cdk isoform known to interact with Cyclin B1 [27]. Both PKCα and 
Cyclin B1 resulted complexed with this enzyme, confirming our previous findings 
(Figure 21d/e). Finally, we performed immunoprecipitation using nuclear or 
cytoplasmic lysates, finding that the interaction between PKCα and Cyclin B1 took 
place in the cytoplasm (Figure 21f). These findings, together with the evidences 
indicating that the kinase activity of PKCα was not linked to Cyclin B1 modulation, 
supported our idea about a possible role for this phosphotransferase as a scaffold protein 
necessary to inhibit the degradation of Cyclin B1 along cell cycle progression.  
                     
                   
 
Figure 21 : PKCα and Cyclin B1 share the same behavior during cell cycle 
progression, highly translocating in the nucleus at G2/M. In addition, they interact 
at cytoplasmic level along cell cycle phases. a) Cells were synchronized as follow: 
G0/G1 cells were starved with HBSS over/night, G1/S cells are cell growing in 
complete RPMI 1640 10% FBS, G2/M cells via Nocodazole. Cell cycle profile was 
analyzed via FACS. b) Cells were synchronized as a). Total, nuclear and cytoplasmic 
lysates were analyzed via Western Blotting to study the expression and the localization 
of PKCα and Cyclin B1. c) Cells were treated as a) and b) and immunocytochemistry 
experiments were performed. d) Co-IP of Cyclin B1/PKCα were performed in cells 
synchronized at G2/M. e) IP of PKCα and Cyclin B1 with Cdk1/cdc2. f) Nuclear and 
cytoplasmic fractions were used to immunoprecipitate Cyclin B1.   
3.2.6 Cyclin B1 nuclear levels are modulated by PKCα  
Since the interaction and co-localization of PKCα and Cyclin B1 was found to take 
place along cell cycle and peak at G2/M, we decided to study if PKCα modulation 
could affect the nuclear translocation of Cyclin B1. In this series of experiments, we 
found that increase or decrease of PKCα levels in the cells, and its related major or 
minor nuclear accumulation, affected Cyclin B1 nuclear import. In order to achieve that, 
we silenced or overexpressed PKCα and, 24h later, we synchronized the cells using 
Nocodazole as previously described. Then, nuclei and cytoplasms were separated and 
lysed. PKCα knock-down cells were characterized by a minor accumulation of Cyclin 
B1 in the cytoplasms and in the nuclei if compared with the controls (Figure 22a) 
(PKCα KD and Scrambled). On the other hand, the samples overexpressing both WT 
and DN isoforms showed a major accumulation in both the compartments (PKCα WT 
OV, PKCα DN OV and Empty vector) (Figure 22b). Data were supported by 
immunocytochemistry (Figure 22c). Taken together, these findings indicated that the 
more PKCα translocated into the nuclei at G2/M the more Cyclin B1 could do the same.  
                 
Figure 22: PKCα modulation regulates Cyclin B1 nuclear translocation. a) PKCα 
was transiently silenced and cells synchronized at G2/M via Nocodazole. Nuclei and 
cytoplasms were separated and lysates analyzed via Western Blotting. b) PKCα was 
transiently overexpressed and cells partially synchronized at G2/M via Nocodazole. 
Nuclei and cytoplasms were separated and lysates analyzed via Western Blotting. c) 
Cells were treated as a) or b) and immunocytochemistry analysis was performed. 
3.2.7 Nuclear DAG oscillations peak at G2/M and trigger the 
accumulation of Cyclin B1 and PKCα into the nucleus 
As the accumulation of Cyclin B1 and PKCα into the nucleus, in particular at G2/M, 
was found, we decided to shed light on the mechanisms through which this event could 
work. Considering that both the proteins are characterized by the lack of a common 
NLS, fundamental for nuclear import of many proteins, we focused our attention on the 
possible factors that could trigger their translocation [31]. Studies performed on 
different cell lines indicated nuclear DAG amount to peak at G2/M and, in turn, act as a 
bait to attract PKC. Then, we focused on DAG production in K562 cells along cell cycle 
progression. Cells were synchronized at G2/M and proliferating cells, G1/S, were used 
as control. Total and nuclear samples were labeled with [3H]-glycerol and lipids were 
extracted. The percentage of total radioactivity corresponding to DAG was analyzed, 
indicating its slight increase in total G2/M extracts compared to the G1/S controls. On 
the other hand, we measured a very important accumulation of this compound in the 
nuclear samples synchronized at G2/M compared to the controls (Figure 23a). This peak 
of nuclear DAG levels, very similar to the findings reported in other studies [52, 53], 
led us to think it could the factor responsible for PKCα and Cyclin B1 nuclear import. 
Then, we treated K562 cells in two different ways: first, we used PMA (PMA 100 nM 
for 30 minutes) in order to mimic an increase of DAG; second, we treated the cells with 
U73122 ( U73122 10µM for 16h), able to inhibit PIP2 hydrolysis mediated by PLC. In 
both the cases we synchronized the cells at G2/M. Western Blotting analyses showed 
that accumulation of PKCα and Cyclin B1 was highly connected with the treatments. 
Indeed, major nuclear import was found in samples treated with PMA, while, on the 
contrary, cells treated with U73122 were characterized by minor levels of the two 
enzymes in the nucleus (Figure 23b). These findings indicated DAG accumulation at 
G2/M checkpoint as the main factor for the localization of PKCα and, in turn, Cyclin 
B1 in the nuclei of K562 cells. 
 
 
 
 
 
    
 
Figure 23 : DAG is responsible for nuclear accumulation of PKCα and Cyclin B1. 
a) Cells were marked with [3H]-glycerol and DAG extracted from total or nuclear 
lysates. Evaluation of the % of radioactivity representing DAG was performed. b) Cells 
were treated with PMA (30 minutes at 100nM) or U73122 (16 hours at 10µM) and 
synchronized at G2/M. Nuclear lysates were analyzed via Western Blotting. 
 
3.2.8 Nuclear PLCβ1 activity is fundamental for DAG production along 
cell cycle progression: this effect leads to modulation in PKCα and 
Cyclin B1 nuclear import at G2/M 
Through the years, several studies indicated the existence of PIP2 related nuclear 
signalling, which leads to production of DAG in the nuclear compartment. Our findings 
showed that nuclear production of DAG raised along cell cycle progression, in 
particular at G2/M. As PIP2 hydrolysis is mediated by PLC isozymes [57], we decided 
to investigate which isoform could be responsible of this mechanism in K562 cells. 
Cells were synchronized in the different cell cycle phases, as previously described, and 
nuclei were separated from cytoplasms (G0/G1, G1/S and G2/M). Next, a screening of 
the localization of different PLC isoforms via Western Blotting was performed, 
indicating PLCβ1 as the only one mainly present in the nuclear compartment (Figure 
24a). These data were confirmed via immunocytochemistry (Figure 24b). Then, we 
transiently silenced this PLC isozyme and we synchronized the cells at G2/M. Nuclear 
and cytoplasmic lysates were analyzed via Western Blotting showing minor PKCα and 
Cyclin B1 accumulation in cells characterized by PLCβ1 knock-down compared to the 
controls transfected with a Scrambled siRNA (PLCβ1 KD and Scrambled) (Figure 24c). 
Finally, in order to further confirm that PLCβ1 was really responsible of this effect on 
PKCα and Cyclin B1, we controlled if its silencing could lead to inhibition of DAG and 
IP3 production. Then, using a PLC assay previously described [47], we analyzed the 
production of IP3 in nuclear extracts of cells synchronized at G2/M. Accordingly with 
our previous findings, we found a strong decrease of IP3 production in nuclei of PLCβ1 
knock-down samples compared with the controls (Figure 24d). All together, these data 
confirmed the importance of nuclear DAG production by PLCβ1 for PKCα and Cyclin 
B1 import into the nucleus at G2/M. 
 
 
 
 
 
Figure 24 : PLCβ1 is the PLC isoform involved in nuclear DAG production and, 
then, in nuclear import of PKCα and Cyclin B1. a) Nuclear and cytoplasmic lysates 
were analyzed via Western Blotting to screen the localization of different PLC isoforms. 
b) Immunocytochemistry  was performed on G1/S cells with a PLCβ1 specific antibody. 
c) Cells were transfected to silence PLCβ1 and, then, synchronized at G2/M via 
Nocodazole. Nuclear and cytoplasmic lysates were analyzed via Western Blotting. d) 
PLC assay was performed in order to study the production of IP3 mediated by PLCβ1. 
 
  
 
 
 
 
 
 
 
 
 
  Discussion 
In these three years as a PhD student I have studied several cellular responses mediated 
by lipid signalling, particularly focusing on the signal transduction processes related to 
PIP2 hydrolysis in the nucleus. As widely reported, different pathways use lipids as 
second messengers, such as Phosphatidylinositol (PI) and its derived [36-38]. Indeed, 
the metabolism of this molecule has been found to influence many processes including 
cell proliferation, cell cycle progression, differentiation, apoptosis and many others. PI 
metabolism consists in a series of coordinated events, which lead to changes in the 
structure of this molecule: several kinases and phosphatases are involved in this process, 
adding or removing phosphate groups to/from different positions on the inositol ring. 
One of the main products of this network is Phosphatidylinositol (4,5)-Biphosphate, 
PI(4,5)P2, which derives by the action of PI kinases that add two phosphates at the 
position 4 and 5 of the inositol ring [36-38]. PI(4,5)P2 can be, then, hydrolyzed by a 
family of lipase, the Phospholipases C (PLC), creating two important second messenger 
for signal transduction: Diacylglycerol (DAG) and Inositol-(1,4,5)-Triphosphate (IP3), 
which in turn triggers Ca2+ release from the Endoplasmic Reticulum (ER) [56] [57]. As 
this series of events have been recognized to take place in the cytoplasm of the cells, in 
the last thirty years it became clear that within the nuclei of eucaryotic cells are all the 
enzymes and substrates to form an inositol signalling completely independent by the 
cytoplasmic one [39, 41, 42]. Indeed, production of DAG has been described in several 
cell models as connected to the action of nuclear isoforms of PLC [47-50]. In particular, 
among different PLC isozymes, PLCβ1 has been widely reported as mainly located in 
the nuclei of different cell lines [57]. This protein is known to be expressed in 
eucaryotic cells in two splicing variants, PLCβ1a and PLCβ1b, which present 
differences in the C-terminus [74]. If PLCβ1b lacks some residues where the NES 
should be located and, then, is localized almost entirely in the nuclei, PLCβ1a is present 
both at nuclear and cytoplasmic levels [86, 87]. However, our previous studies indicated 
PLCβ1 as a fundamental protagonist of many cellular responses, such as cell cycle 
progression and cell differentiation [100, 101] [102] [103]. Analyses performed on 
MEL cells treated with DMSO indicated that a diminished amount of nuclear PIP2 
hydrolysis was necessary for the cells to undergo differentiation [39, 46, 93, 99]. Then, 
experiments of overexpression of nuclear PLCβ1 inhibited the differentiative process 
through an increase in the production of DAG and IP3 into the nucleus of the cells [100, 
101]. Moreover, nuclear PLCβ1 was described very important both during G1/S 
transition and G2/M progression of the cell cycle. Evidences collected in MEL and 
Swiss 3t3 cells indicated PLCβ1 as responsible of a positive regulation of a D type 
Cyclin, precisely Cyclin D3, known to play a fundamental role in the G1/S checkpoint 
[102, 146]. In particular, only up-regulation of the nuclear enzyme was necessary for 
Cyclin D3 modulation and, in turn, for the strong prolongation of the S phase of the cell 
cycle. On the other hand, several reports indicated an increase of nuclear PLC activity at 
G2/M, seen as a major production of DAG in the nuclear compartment, which, in turn, 
could attract some conventional PKC isoforms, such as PKCα and PKCβII [103] [135]. 
These enzymes are Ser/Thr phosphotransferases highly dependent by the PLC 
signalling; indeed, production of DAG and IP3, with the subsequent Ca2+ release from 
ER, are indispensable for their maturation and activation [104-106]. PKC have been 
widely indicated as cell cycle modulators and their role resulted to be highly connected 
to different cell models and signalling environments [104-106]. In particular, PKC are 
known to be able to translocate into the nucleus at G2/M  where they contribute to 
phosphorylate Lamins, triggering the disassembly of nuclear envelope during mitosis 
[103] [135] [141].  
 
Since most of all the studies on PLC/PKC signalling and cell cycle were performed on 
murine models, my purpose was to investigate its possible involvement in human cell 
lines, in terms of cell proliferation and cell cycle modulation. In order to achieve that, 
we used a human erythroleukemia cell line, K562, as a homologue of MEL cells. The 
utilization of this particular cell line took some advantages in our research. Indeed, 
K562 cells resulted a very good model for our purpose for some characteristics they 
possess: a very fast doubling time (about 24h), presence of high quantity of PLCβ1 in 
the nucleus and expression of only two conventional PKC isoforms, PKCα and PKCβII 
[143]. The first part of my work was focused on G1/S transition, while the second was 
concentrated on G2/M progression.  
 
As PLCβ1 was found connected to Cyclin D3 in MEL cells, even if the mechanism was 
not perfectly elucidated, we firstly studied if this link was still present in our model. 
Then, we transiently overexpressed PLCβ1a and PLCβ1b in K562 cells, finding that 
both the isoforms were able to lead to an up-modulation of Cyclin D3 levels. These 
effects appeared to be specific because other proteins involved in cell cycle machinery 
were not affected at all. Next, we decided to create clones stably overexpressing 
PLCβ1a or PLCβ1b. Working on cells stably transfected presents strengths and 
weaknesses: the most important advantage can be synthesized in having an entire 
population of cells transfected (about 100%) and in avoiding the transfection process, 
usually quite harmful for the cells; on the other hand, a continuous overexpression of a 
protein like PLCβ1 can influence many different pathways in time. In order to 
overcome this problem, clones were kept in proliferation for up two weeks. Since both 
the clones overexpressing the two isoforms of PLCβ1 presented an upregulation of 
Cyclin D3, we studied the profile of their cell cycle progression. After synchronization, 
performed by a 24h starvation, proliferating cells with PLCβ1 overexpressed showed a 
prolonged S phase of the cell cycle, probably due to the upregulation of Cyclin D3. 
Indeed, D type cyclins concur in the G1/S transition, through the activity of the Cdk 
isoforms which they complex, Cdk4/6, capable to phosphorylate pRB leading to the 
release of the E2F and, in turn, to G1/S transition [19]. Moreover, as indicated by 
experiments of cell counting, this led to a decrease of the proliferation of the clones, 
probably due to the prolonged S phase. Next, we decided to better elucidate this 
mechanism and we focused on the direct down-stream of PLC signalling, conventional 
PKC isoforms, represented in K562 cells by PKCα and PKCβII. Our findings indicated 
that PKCα was downmodulated by PLCβ1 overexpression, while PKCβII was not 
affected at all. This peculiar effect was probably amenable to one of the most important 
characteristics of PKC: indeed, if they are chronically or highly activated, these protein 
undergo modifications on their structure and become more easily degradable [131, 132]. 
In order to understand if PLCβ1 activity was really involved in the system, we 
overexpressed two catalytic inactive isoforms of PLCβ1 characterized by two puntiform 
mutations on the residues His331 and His378, which inhibited their activity [64]. This 
mutagenesis process was performed  and analyzed accordingly with previous studies of 
the catalytic domain of PLCδ1 [62, 63]. However, the data confirmed the idea that 
PLCβ1 overexpression was linked to PKCα decrease. Indeed, the two mutants did not 
affect levels of PKCα at all. Finally, we decided to act directly on PKCα. In a few 
words, we silenced it, in order to mimic the effects of PLCβ1 overexpression on its 
expression, and we found that cells characterized by PKC knock-down showed the same 
up-regulation of Cyclin D3 and the same slow-down in cell proliferation encountered in 
the clones. All together our data demonstrated the existence of a PLCβ1/PKCα 
mediated pathway which could affect cell proliferation through Cyclin D3 modulation.  
  
In the second part of my three years PhD course, I focused my attention on the G2/M 
checkpoint of the cell cycle and the role of proteins connected with PIP2 in this phase. 
In particular, I studied the possible involvement of PKC in the regulation of Cyclin 
B1/Cdk1, never found before. As widely reported in literature, the modulation of cell 
proliferation by these phosphotransferases has been showed as highly context dependent 
both in terms of cell models and signalling environment. Many studies were performed 
on different cell lines describing growth stimulatory or inhibitory effects for PKC. 
Through the years, regulation of Cyclins, Cdks, cell cycle inhibitors and Lamins has 
been showed directly connected with the activity, the localization and the expression of 
many PKC isoforms [55, 106, 133]. Previous reports by our laboratory indicated PKC 
involved in the G2/M progression through the phosphorylation of Lamins [103] [135] 
[141]. Indeed, nuclear translocation of PKCα in MEL cells was found to help nuclear 
envelope disassembly at mitosis. These findings confirmed other studies performed on 
AML cell lines, such as HL60 [135] [141]. Since nothing was ever found about the 
possible connection between PKC and Cyclin B1/Cdk1 complex, we decided to 
understand if in our model, K562 cells, some relationship could exist affecting cell 
cycle progression. First, we treated the cells with three different PKC inhibitors, specific 
for conventional and novel isoforms: Go6983, Go6976 and PKC inhibitor*. These 
compounds shared the capacity to inhibit PKC activity, acting as ATP-competitors on 
the ATP-binding site [144]. In particular, interesting was the ability of PKC inhibitor* 
to lead the enzymes to a strong decrease in terms of expression, effect not encountered 
with Go6983 and Go6976. As this modulation was found not to be connected with a 
regulation of the gene expression of PKC, it was probably due to off target effects of the 
compound which could interfere with PKC life cycle. Particularly, for every 
experiment, we decided to synchronize the cells at G2/M using Nocodazole, in order to 
avoid any oscillation of Cyclin B1 expression related to different cell cycle phases. 
Then, we found an important decrease of Cyclin B1 levels only in samples treated with 
PKC inhibitor*, while Go6983 and Go6976 had no effects on this enzyme. On the 
contrary, we hyper-stimulated PKC signalling using PMA, a phorbol-ester known as a 
potent activator of these enzymes [131, 132]. Cells blocked at G2/M showed a strong 
decrease of PKC levels, due to their hyperactivation (see PKC life cycle chapter), and a 
subsequent downmodulation of Cyclin B1 expression. These effects were very similar 
to the ones encountered inhibiting PKC with PKC inhibitor*, indicating that only the 
modulation of the activity of these proteins was not sufficient for Cyclin B1 regulation; 
on the contrary, their physical presence in the system seemed to be necessary. However, 
since many inhibitors are known to have many side effects, we focused our attention on 
understanding if PKC were really involved in this mechanism and, in particular, which 
conventional isoform between PKCα and PKCβII. Experiments of silencing of these 
two isozymes indicated PKCα as the main responsible for Cyclin B1 modulation. 
Notably, analyses via FACS of the cell cycle profile of cells characterized by 
PKCα knock-down showed their accumulation at G2/M, probably due to difficulties in 
the exit from this phase for the lack of Cyclin B1, fundamental for the mitotic 
machinery [27]. Next, we decided to understand if the catalytic activity of PKCα was 
really necessary in this process. In order to achieve that, we used the same approach 
described for the study of the lipase activity of PLCβ1: we transfected the cells with two 
different vectors encoding a Wild Type and a Dominant Negative (catalytic inactive) 
form of PKCα finding the same up-regulation of Cyclin B1 and the same G2/M 
accumulation under Nocodazole stimulation. These findings further indicated that the 
physical presence of PKCα was more important than its activity for the process. 
Moreover, we studied at which level this regulation could take place. Particularly, we 
analyzed the gene expression of Cyclin B1 via real-time PCR after modulation of 
PKCα. No changes were found, indicating a possible post-transcriptional mechanism. 
As Cyclin B1 levels oscillate along the different phases of cell cycle degrading after 
G2/M exit [27, 147], we thought PKCα could be involved in this process. Then, we 
silenced PKCα and we treated our cells with a proteasome inhibitor, MG-132, in order 
to inhibit Cyclin B1 degradation. The cells were characterized by an important 
accumulation of this enzyme, probably due to the block of its degradation connected 
with the lack of PKCα. As further demonstration of that, we found an increase of the 
expression of p21/Cip1 in cells with PKCα knock-down. This enzyme is commonly 
described as an inhibitor of cell cycle progression, acting both at G1/S and G2/M 
checkpoints and targeting different cyclins. In particular, recent studies reported its 
strong accumulation and involvement in Cyclin B1 degradation after DNA damage. 
Here, we found that silencing PKCα led to an important decrease in Cyclin B1 and a 
concomitant accumulation of p21/Cip1 in the cells as well as it was described in 
literature [34]. All together, our findings indicated an involvement of PKCα in Cyclin 
B1 degradation. Next, in order to better understand the connection between these 
proteins, we decided to study their behavior along cell cycle progression. We set a 
protocol to stimulate synchronization of K562 cells in the different cell cycle phases 
(see materials and methods) and we found that both the enzymes increased along cell 
cycle progression, peaking at G2/M. In particular, we found their high accumulation 
into the nucleus during mitosis. Moreover, experiments of Co-Immunoprecipitation 
showed PKCα and Cyclin B1 capable to interact along cell cycle in the cytoplasmic 
fraction. These findings supported the idea of PKCα acting as a scaffold protein for 
Cyclin B1 in order to avoid its degradation along cell cycle progression. Finally, we 
decided to shed light on the possible mechanism through which these enzymes could 
translocate in the nucleus at G2/M. As previously reported, both of them are 
characterized by the lack of a common NLS, which is usually necessary for the import 
of proteins through the karyopherin/importin system [31]. Then, we focused on the 
possible factor that could trigger this process. Through the years, many studies indicated 
DAG production in the nuclear compartment as the possible explanation for PKC 
import [47-50]. In order to study the role of DAG in K562 cells, we analyzed its 
production in total or nuclear lysates, finding it highly accumulated in the nucleus at 
G2/M checkpoint. Thus, we mimicked DAG modulations, in terms of increase or 
decrease, through the treatment of the cells with either PMA or U73122 (PLC inhibitor) 
respectively. As PMA action has already been described in this thesis, U73122 effects 
led to inhibition of PIP2 hydrolysis mediated by PLC and, then, to a minor production of 
DAG. The evidences emerging by these experiments showed that PKCα and Cyclin B1 
nuclear levels were highly connected to the treatments and, in turn, to DAG amount in 
the nucleus at G2/M checkpoint. Several studies in the 90's were performed to 
investigate different pathways involved in the production of DAG into the nucleus [47-
50]. Although reports on thrombin-stimulated cells indicated DAG could derive from a 
phosphatidylcholine mediated pathway, others showed nuclear inositides as the main 
resource for this process [148]. Accordingly to this, we focused on the study of different 
PLC isoforms in order to identify which one was responsible for PIP2 hydrolysis in the 
nucleus of K562 cells. Our findings reported that PLCβ1 was the only isoform mainly 
localized in the nucleus of K562 cells. In particular, the silencing of this isozyme led to 
minor accumulation of PKCα and Cyclin B1 in the nucleus of cells synchronized at 
G2/M by Nocodazole. Finally, to confirm that PLCβ1 silencing could inhibit PIP2 
hydrolysis in the nucleus, we analyzed the production of IP3 through a PLC assay 
described by Martelli et al [47]. As expected, IP3 levels in the nucleus of cells 
characterized by PLCβ1 knock-down were highly reduced if compared with the 
controls, indicating this isoform as very important for DAG production along cell cycle 
and, in turn, for nuclear translocation of PKCα and Cyclin B1 at G2/M checkpoint.  
 
All together, the findings described in this thesis indicate new roles for PLCβ1 and 
PKCα in the regulation of cell cycle, both at G1/S and G2/M levels. In particular, DAG 
production by PLCβ1 seems to be fundamental in the control of activity and location of 
PKCα, which, in turn, was found connected with these two cell cycle phases through 
the modulation of Cyclin D3 and Cyclin B1. The theorized mechanisms of cell cycle 
control are schematically reported in Figure 25. 
 
The future perspectives derived by our data are many. First, the role of PKC isozymes 
in Cyclin B1 modulation must be further elucidated. Indeed, how this mechanism works 
and where/when is still not really clear. Second, the involvement of another class of 
proteins highly connected with nuclear DAG production, the Diacylglycerol Kinase 
family (DGK), could be very important for the regulation of cell cycle. These are 
enzymes able to catalyze the conversion of DAG in Phosphatidic Acid (PA) through the 
utilization of ATP as a source of phosphates [149]. Several findings reported their 
possible involvement in the exit from G2/M, since their activity seems to raise at the 
end of the mitotic process, probably to modulate nuclear DAG amount and allow the 
cells to divide [150]. Finally, spreading our findings on other cell models would be of 
high interest. As Cyclin B1 degradation has been deeply described on cervical cancer 
cells (Hela), it will be very important to find out if the connection between PKC and 
Cyclin B1 exists also in this model and, then, if it could be useful to elucidate the 
mechanisms of nuclear import of this protein [27, 147]. The nuclear lipid pool changes 
along cell cycle and can be seen as one of the main reason for the shuttle inside and 
outside the nuclei of many proteins characterized by absence of a common nuclear 
localization signal, including Cyclin B1.  
 
 
 
 
     
           
  
 
 
         
 
Figure 25. Schematic representation of cell cycle modulation by DAG production 
mediated by PLCβ1 in K562 cell line. PLCβ1 activity is fundamental in the 
production of DAG in the nuclei of K562. A chronic overexpression of this enzyme leads 
to an increased activity of PKCα, which, in turn, undergoes faster degradation. This 
affects G1/S transition through the raise of Cyclin D3 expression. On the other hand, 
nuclear DAG production levels raise at G2/M thanks to PLCβ1 activity, modulating 
PKCα and Cyclin B1 nuclear accumulation. In addition, PKCα interacts with Cyclin 
B1 at a cytoplasmic level avoiding its fast degradation and helping its nuclear import. 
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